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ABSTRACT

DEVELOPMENT OF HINT BASED COMPUTATIONAL TOOLS FOR DRUG
DESIGN: APPLICATIONS IN THE DESIGN AND DEVELOPMENT OF NOVEL
ANTI-CANCER AGENTS

By
Ashutosh Tripathi Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Glen E. Kellogg, Ph.D.
Associate Professor, Department of Medicinal Chemistry
Institute for Structural Biology & Drug Discovery

The overall aim of the research is to develop a computational platform based on HINT
paradigm for manipulating, predicting and analyzing biomacromolecular-ligand structure.
A second synergistic goal is to apply the above methodology to design novel and potent
anti-cancer agents.

xvii

The crucial role of the microtubule in cell division has identified tubulin as an interesting
target for the development of therapeutics for cancer. Pyrrole-containing molecules derived
from nature have proven to be particularly useful as lead compounds for drug
development. We have designed and developed a series of substituted pyrroles that inhibit
growth and promote death of breast tumor cells at nM and μM concentrations in human
breast tumor cell lines. In another project, stilbene analogs were designed and developed
as microtubule depolymerizing agents that showed anti-leukemic activity. A molecular
modeling study was carried out to accurately represent the complex structure and the
binding mode of a new class of tubulin inhibitors that bind at the αβ-tubulin colchicine site.
These studies coupled with HINT interaction analyses were able to describe the complex
structure and the binding modes of inhibitors. Qualitative analyses of the results showed
general agreement with the experimental in vitro biological activity for these derivatives.
Consequently, we have been designing new analogs that can be synthesized and tested; we
believe that these molecules will be highly selective against cancer cells with minimal
toxicity to the host tissue.

Another goal of our research is to develop computational tools for drug design. The
development and implementation of a novel cavity detection algorithm is also reported and
discussed. The algorithm named VICE (Vectorial Identification of Cavity Extents) utilizes
HINT toolkit functions to identify and delineate a binding pocket in a protein. The program
is based on geometric criteria and applies simple integer grid maps to delineate binding

xviii

sites. The algorithm was extensively tested on a diverse set of proteins and detects binding
pockets of different shapes and sizes.

The study also implemented the computational titration algorithm to understand the
complexity of ligand binding and protonation state in the active site of HIV-1 protease.
The Computational titration algorithm is a powerful tool for understanding ligand binding
in a complex biochemical environment and allows generating hypothesis on the best model
for binding.

xix

CHAPTER 1

Computer-Aided Drug Design: Introduction and Applications in
Anti-Cancer Drug Design

1.1 Introduction
1.1.1 Cancer Therapy
Cancer is a group of diseases in which there is an uncontrolled multiplication and spread
of the body’s own cells within body in abnormal forms. Cancer may affect almost any
tissue of the body and may metastasize to other tissues within the body. If the spread is
not controlled, it can result in death. According to the American Cancer Society’s ‘Global
Cancer Facts & Figures 2007’ and ‘Cancer Facts & Figures 2008’ cancer is the second
leading cause of deaths after heart disease in developed countries and third leading cause
of death in developing countries1,2. According to a report released by WHO, it is
estimated that there will be 16 million new cases every year by 2020 and by 2050, the
global burden is expected to grow to 27 million new cancer cases3,4.

Despite

considerable progress in its diagnosis and treatment cancer continues to be one of the
major health and socio-economic problems.
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Over the last couple of decades, research has revealed considerable information about the
molecular biology, pathobiochemistry and the intricate pathways involved in cancer5,6.
Multiple factors are involved in the initiation, promotion and progression of cancer which
lead to changes in the host genome and aberrant expression of oncogenes or tumor
suppressor genes7-9. The abnormal cell multiplication and spread can be attributed to both
external and internal factors. External factors like tobacco, chemicals, some viruses and
radiations can cause mutations. These mutations cause altered gene expression which
may activate protooncogenes to oncogenes like erbB, ras, myc etc.8,10,11. This, in turn,
may result in uncontrolled cell proliferation and dedifferentiation. In-addition, inherited
mutations in metabolism and certain immune conditions can cause expression of
oncogenes11,12. These inadvertent factors may act together or in sequence to initiate or
promote carcinogenesis and develop primary tumor, which, subsequently develops into a
full fledged malignant tumor.

Over the past decade, a number of chemotherapeutic drugs with different mechanism of
actions and targeting various stages of metastatic cell growth have flooded the
pharmaceutical market13,14. Based on their mechanism of action, these drugs can be
classified into different classes as alkylating agents, antimetabolites, antibiotics,
nucleoside analogues, antimitotic agents, etc15. However, most of these drugs are
associated with severe toxicities and are not effective against all types of cancer. Thus,
the search for new anticancer drugs and the development of more effective treatment
strategies continues to be imperative16.
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Until recently, anti-cancer drug discovery had extensively focused on the critical cell
growth stage, mitosis, and any alteration or miscontrol of which can lead to development
of human tumors. After the clinical success of taxol, microtubules have received
considerable attention as the potential targets in the drug discovery process17-19.
Microtubules form the cytoskeleton of a cell and are critical in mitosis and cell division.
Tubulin, a heterodimeric protein forms the fundamental structural unit of a microtubule
and joins in a head-to-tail fashion to form a long, filamentous protofilament. These
protofilaments join laterally to form a hollow tube shaped protein polymer, the
microtubule, which forms a mesh like network in eukaryotic cells. Besides playing an
important role in mitosis, microtubules are involved in diverse cellular processes such as
locomotion and intracellular transport. In addition, they play an important role in the
development and maintenance of cell shape, signaling and transport of cellular
components such as vesicles, mitochondria, etc. Thus, microtubules become an important
target for anticancer drugs18. Since chemically diverse groups of anti-mitotic drugs that
target microtubules and induce mitotic arrest have been used with great success against
cancer, microtubules are considered as one of the best identified cancer targets17,18.
However, research in this area is held back due to lack of a high resolution crystal
structure that will aid in efficient structure-based drug design. Although there are several
drugs which bind to tubulin protein and disrupt microtubule dynamics19, their clinical
usefulness is limited by their unfavorable pharmacokinetic profiles and side effects.
Furthermore, the limited availability and complexity in synthesis of pharmacologically
active lead compounds and their chemical modification presents a major obstacle in
improving the overall profile of a drug candidate. The complexity in development of anti-
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cancer chemotherapeutics makes it difficult to treat the disease and as a result it is
necessary to come up with a rational program to identify potent leads that will stimulate
the development of more effective anti-cancer chemotherapeutics.

1.1.2 Drug Discovery
Traditionally the strategy for discovering new drugs consisted of random screening of
thousands of compounds derived from natural products to identify a lead20. Taking this
lead structure, a program is developed for finding analogs exhibiting the desired
biological properties. However, this entire process is highly laborious, expensive and
conceptually inelegant. During last couple of decades pharmaceutical industry has
experienced a paradigm shift in its approach to discover drugs. The traditional methods of
drug discovery are now being supplemented by some more direct approaches which are
derived from the understanding of the molecular processes involved in the underlying
disease. Pure samples of protein targets are now being isolated and the three dimensional
structure of both ligand and target site may be determined by X-ray crystallography or
computational methods. It is now possible to learn how precisely topography of
structures control the regulation of life processes. In order to further such progress, a
rational approach to drug discovery has emerged in the pharmaceutical industry and has
contributed to the rapid development of active candidates. New molecules are conceived
either on the basis of the similarities they share with the known lead compound or their
complementarities with 3D structures of known active sites21-23.

4

Understanding the three-dimensional aspects of drug-receptor interactions and their
specificity at the molecular level has become a focal point in the modern drug discovery.
Recent advances in genomics, bioinformatics, high-throughput screening and
combinatorial synthesis are providing valuable inputs for the small molecular leads.
However, optimizing the chemical and biochemical properties of a lead warrants
substantial resources, which, in turn, will assist in the rational selection of “druggable”
chemical entities, i.e., the selection of drug candidates/chemical entities that are more
likely to have favorable characteristics for the treatment of human disease, thus
improving the efficiency of the drug discovery/development process24.

The drug discovery process is an interplay between computational and experimental
approaches. Computer-aided drug design contributes to the understanding of
biomolecular processes in a qualitative and quantitative way. It not only presents means
for analyzing the details of the molecular machinery involved in a system and
understanding the way the biological system functions, but also, provides the tools for
predicting potential possibilities of the prototype candidate molecules. The techniques
currently available provide extensive insights into the precise molecular features that are
responsible for the regulation of the biological processes. These structural and
physicochemical characteristics are of primary importance in understanding the structure
–activity relationships and hence, the rational design of drug. Computer-aided drug
design has opened the way to the discovery of lead molecules by a rational approach, and
its central role in rational drug design has become fully apparent25.
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1.1.3 Computer-Aided Molecular Design
Computer-aided molecular design is expected to contribute to the discovery of novel
molecules conceived on the basis of precise three dimensional stereochemical and
physicochemical considerations. Systematic investigation of 3D stereochemical and
physicochemical features of a protein and its binding site are crucial for designing small
molecules that modulate protein functions. The ability to accurately predict binding mode
from computer simulations is an invaluable resource in understanding biochemical
process and drug action. Several aspects of molecular recognition can be discerned from
the computational modeling of protein-ligand complex. Predicting the affinity of a new
putative inhibitor for a macromolecular receptor is therefore imperative for designing of
more potent analogs. Though structural data available from x-ray crystallography and
NMR has undeniably encouraged the efforts towards understanding the biological
complexity of molecular recognition, fundamental uncertainties in binding site
interactions and insufficient knowledge of well defined binding pockets are a major
bottleneck in designing effective drugs with optimal activity.

One important aspect in modeling bio-molecular systems or molecular recognition events
is to accurately model the energetics of the binding. Although computational tools have
been used to corroborate experimental data, the interaction energies calculated without
the pH, ionization and entropic contributions are not always expected to correlate well
with the experimentally measured free energies of binding. Subtle variations in
microenvironment of a protein due to changes in experimental conditions such as pH,
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buffer, ionic strength and temperature can influence the bio-molecular interactions and
complex formation26. The primary goal of modeling studies is to accurately simulate the
microenvironment of an active site. Calculation of binding free energy involves
evaluation of both enthalpic and entropic contributions and forms an integral part of
structure-based drug design protocol27,28. A meaningful description of the system can be
obtained from thermodynamic analysis of protein-ligand interaction. To date, several
structure-based modeling methods have been developed that give vital insight into the
free energy changes of the system. Some of these methods viz. Free Energy Perturbation
(FEP), Linear Interaction Energy (LIE), and Molecular Mechanics Poisson-Boltzmann
Surface area (MM-PBSA) calculations involve extensive sampling of conformational
states. However, the computational cost and human interaction necessary to perform
these calculations make them less applicable for screening of a very large number of
compounds and more viable in a later phase of drug design. These models can contribute
significantly to the understanding of structural and energetic basis of protein-ligand
interactions and hence, the structure-based design of novel compounds. Virtual screening
methods involving database searching and docking tools along with de novo drug design
tools facilitate identification and optimization of lead candidate. This research proposes
the development and application of such tools to identify new anti-cancer drugs. In the
subsequent subsections, the role of different computational approaches and the research
plan to design and develop novel anti-cancer agents will be discussed. In section 1.2 we
start with a brief review of approaches and technologies used in structure-based drug
design. In the subsequent section 1.3 we highlight the HINT model and describe the
Toolkit design. In the next section 1.4 we present a research plan for the design and
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development of computational tools and their application in designing novel anti-cancer
agents.

1.2 Structure-Based Drug Design
The purpose of structure-based drug design is to identify or construct molecules that bind
with high affinity to a structurally defined binding site of a target protein. It is the process
of using the three-dimensional structural information from a macromolecular target
or/and ligand-target complexes to design novel drugs that may modulate target protein for
desired activity. Recent computational approaches facilitate extraction of all the relevant
information from available structures to understand specific molecular recognition events
and to elucidate the function of the target macromolecule29.

Structure-based drug design uses an efficient and intelligent approach to design improved
ligands for the target24. The first step in structure-based drug design is the elucidation of
three-dimensional structure of the target macromolecule (protein or nucleic acid) by Xray crystallography or NMR. In some cases, where direct structural information is
unavailable, a homology model can be used as the starting point. However, there are
instances where the function of a protein is unknown or the domain responsible for the
activity is unidentified. Several methods are available for identification and
characterization of the active site30,31. These programs can be sorted into different
categories according to the approach they take to identify and delineate the active site (i)
Evolutionary methods (structure/sequence alignments) (ii) probe/energy-based methods
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(iii) geometric approaches. All these methods are likely to evolve with the availability of
more structural and sequence data from structural genomics projects.

Recent advances in combinatorial chemistry, high throughput chemical synthesis and
screening are providing valuable inputs for the identification of small molecular
leads21,22,32. Once a lead compound has been identified, an iterative process of lead
optimization begins that involves solving the three-dimensional structure of the lead
compound bound to the target. Development of new computational drug design tools
facilitates examination and characterization of the complex structure and the types of
interactions that the bound ligand makes with the protein. The binding site specifies
structural and physicochemical constraints that must be met by any putative ligand.
Hence, it is imperative to analyze the binding site by mapping the characteristics that are
essential for ligand recognition. Besides shape complementarity, which plays an
important role in protein–ligand interactions, physicochemical complementarity is
essential for the specificity of binding33.

Many promising approaches towards the goal of automated ligand design and
optimization have been reported34-37. In particular, there has been a surge in new methods
in the past few years, greatly extending the approaches to ligand design. Lead
optimization methods may involve improvements to existing lead compounds by
introducing new functionality to the lead scaffold. A combinatorial library, thus
generated, is screened against the target protein. Although, the approach is rational and
has been successfully applied, the analogs generated are very similar to the lead
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compound and this limits the discovery of diverse library of compounds. In another
widely used and more successful approach, large databases of compounds are virtually
screened23. It is a two pronged approach, in which, while maintaining pharmacophoric
constraints on one hand, new lead compounds with different scaffolds can be identified,
thereby, introducing diversity to the compound library. These virtual screening methods
take each proposed ligand and attempt to position it in the active site of the receptor, or
match it to a pharmacophore model38. The compounds are scored and ranked based on
their steric and physicochemical complementarity with the target site and the best
compounds are tested with biochemical assays39. Another promising approach to generate
entire novel series of compounds is de novo lead generation programs36. In contrast to the
whole molecule docking approach, in de novo methods, fragments of molecules, usually
small functional groups are docked into the site, scored, and linked together using
different scaffolds. The methodology allows the diverse set of fragments to exhaustively
explore the binding site. The final in silico library of compounds can be scored, ranked
and synthesized in the laboratory. However, the main drawback with this approach is the
stability and synthetic feasibility of the compound suggested. There are many excellent
drug design software methods available capable of either virtual screening or de novo
generation36,40. However, the main advantage of virtual screening from a database is that
the hit compounds can normally be purchased and tested easily. The success of all these
approaches depends on how well the protein-ligand complex is characterized and scored.
Various techniques have proven to be efficient tools for generating near-native
conformations of complexes41. However, there are still some inherent limitations that
need to be addressed. The robustness of any computational approach depends on how
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accurately the experimental information is derived and parameterized to simulate a
biological system. Due to the multiplicity of factors controlling the binding in any
biological system, the phenomenon is particularly difficult to model computationally.
Thus the most demanding and rewarding answer to this problem is hoped to lie in rational
drug design.

1.2.1 Microenvironment & Active Site
Molecular interactions are regulated by subtle recognition and discrimination patterns
where three dimensional features and microenvironment of the active site plays a vital
role. The first step in any rational drug design protocol is to identify and elucidate the
active site in a protein molecule. These active sites themselves might not be observed
from an initial inspection. Protein surfaces are formed by numerous cavities and
protrusions that are interlinked through small narrow channels and more than often
interspersed with numerous holes/voids. The size and shape of protein cavities dictates
the three-dimensional geometry of ligands and guides the important intermolecular
interactions that mediate binding. The study of cavities may give an insight into the
mechanism of such interactions and might help in the design of novel ligands, substrates
or inhibitors. The determination of binding pockets is, therefore, an important step
towards the rational design of novel ligands. An in-depth analysis and classification of
pockets on the surface of protein structures might also improve our understanding of the
processes involved in structure-based drug design.
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A number of successful methods have been developed for predicting ligand binding
sites30. These methods basically take different approaches depending on the kind of
information available. Evolutionary methods apply a heuristic approach by finding
characteristic sequence patterns based on structure/sequence alignments. The presence
and evolutionary conservation of certain residue pairs, cofactors, metal ions and binding
motifs can, therefore, give useful clues for deducing the biochemical function of an
uncharacterized protein and location of the binding sites. These computational methods
are useful for predicting the location of binding sites when direct experimental
information is unavailable.

Methods that use structural information, when available, are particularly promising since
they can potentially identify and characterize an active site based on the properties of the
pocket. These methods apply energy/probe to generate functional maps of the binding
site indicating the most favorable regions for placing ligand groups with similar
properties to the probes. The atomic details can be further evaluated by mapping the
physicochemical properties of the binding surface such as hydrophobicity or electrostatic
potentials.

The properties/microenvironment of the cavity are responsible for the substrate
specificity. Theoretical calculations simulating the microenvironment of binding site are
plagued by very drastic approximations. The phenomena of solvation/desolvation and the
effects of varying pH and electrostatics are difficult to model computationally. Under
physiological conditions a protein (enzyme/receptor) is present in a milieu of solvents,
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even after crystallization a protein crystal may contain upto 70% of solvent42, which
includes the buffer solution as well. Exposure of protein crystal structure to these solvents
and buffers during crystallization may affect the microenvironment of active site as these
solvent molecules may distribute themselves within the different pH zones or solvent
channels according to the nature of the residues lining these solvent pockets. The altered
microenvironment may influence the ligand binding43 due to change in the protonation
states of the active site residues. The binding of ligand/small molecule to biological
macromolecules is further complicated by peculiarities in the metal ion binding, preferred
coordination numbers, relative affinity for specific ions, and preferred binding orientation
and the lowest energy ionization state. It is, thus, not always possible to accurately
resolve the biological microenvironment experimentally or to model it computationally.
Thus calculation of optimum ionization/protonation state of complex formation is crucial
for understanding binding process and step towards desigining more selective ligands.

1.2.2 Mapping the Binding Site
Structural and physicochemical characterization of an active site has become a major goal
in drug discovery44. Understanding the chemistry behind molecular recognition is a
central issue in drug design. With the advances in experimental techniques of X-ray
crystallography and NMR, the elucidation of binding features on a protein structure has
become more convenient. The computational mapping of a binding site to generate a
pharmacophore model directly from a protein crystal structure can reveal key elements in
protein-ligand binding45. Such knowledge is indispensable for rational drug design, since
in majority of cases, receptor–drug interactions are specific in nature. Correctly mapping
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the binding site is an important step in structure-based drug design and can be used as the
starting point for finding new lead compounds or drug candidates46.

The structure-based mapping of binding site or receptor-based pharmacophore generation
provides an ensemble of steric and electronic features that ensures optimal interactions
with a specific biological target structure, although a pharmacophore can be calculated
from both ligands or/and protein structure47. A receptor-based pharmacophore defines
essential features for molecular recognition and receptor-ligand interaction48. Structurebased mapping uses features complementary to a protein site to define the shape and
physiochemical constraint of the target site49. The mapping of crucial features is
challenging since the number of ‘Hot Spots’ and their strength is critical for hypothesis
generation. This facilitates the docking process by defining a set of constraints that can be
quantified in terms of how many and which pharmacophoric points can be matched by a
ligand or a library of compounds.

A Receptor-based pharmacophore can be defined as an arrangement in three-dimensional
space of several (typically three to six) features considered to be relevant for specific
binding50. These features can be specific such as hydrogen bond donor or acceptor, or
aromatic moiety. These physicochemical attributes can be mapped on a cavity surface
using different approaches based on surface conservation or energetic contouring with
interacting molecular probes51. However, the challenge is to pinpoint the specific
electrostatic or hydrophobic interactions complementary to the residues lining the active
site. To some extent, probe-based methods have found success in defining the polar and
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hydrophobic regions within the cavity52. The knowledge-based approach of assigning
interaction sites have also been implemented (LUDI) where statistical analysis of
hydrogen bond patterns and geometries in crystal packing is taken into account by
generating an ensemble of interaction sites distributed over the region of acceptable
geometries53. Similarly diffused/non-directional interactions such as hydrophobic
interactions due to aliphatic or aromatic moiety can be assigned after study of its
distribution pattern. This approach has the advantage that it is purely geometrical and
therefore avoids costly calculations of potential energy functions53.

While geometric matching and pinpointing of specific interactions between ligand and
receptor atoms provides a very intuitive picture, it is clear from basic physical principles
and from measurements that the energetics involved in the thermodynamic association
and dissociation processes determines the binding affinity of the ligand, which, after all,
is one of the key properties of a molecule in the drug discovery process. Pharmacophores
do not encode these energetic aspects, but do provide a rough sketch of the binding
pocket. The potential binding pockets are considered as binding sites if a small molecule
can bind in pocket such that it can form sufficient energetically favorable interactions
with the protein. Numerous other techniques and approaches have been developed to
calculate binding energies28,54. This has important implications in understanding of the
nature of protein interactions, identifying the suitability of sites as drug targets and for
identifying critical regions for docking and structure-based drug design.
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1.2.3 Docking
Docking calculations are needed to predict how new hypothetical or existing compounds
will bind to the protein. Given the three dimensional structure of a receptor, known
ligands can be docked to examine how they fit so that a protein ligand complex can be
characterized in detail and modifications that improve binding can be suggested. The
docking methodology has found widespread applications in drug discovery since large
number of small molecules can be virtually screened by docking compounds from a
database into a receptor structure in an attempt to find novel compounds39,55.

The docking approach can be thought of as a three step process. The first step involves
characterization of binding site. This step identifies and delineates the binding site for
docking. It is a critical step as it defines and sets the constraints to position the ligand in
the defined binding region. The second step is to correctly position a set of ligands in the
binding site based on the defined constraints. This step involves exploration of the
configurational and conformational space for the interaction between target and the
ligand. This step tries to correctly predict and identify the most favorable binding mode
of the ligand into the target active site. The third step is an elaborate process of
energetically assessing the docked position of ligand and scoring and ranking the
proposed protein-ligand complex.

Although the first step of site characterization is crucial for docking, it is generally not
considered to be a part of docking methodology as it has grown and developed as a
separate field of study. This broadly leaves the docking approach as a two component
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approach of ‘search’ and ‘scoring’. Several different approaches have been developed for
investigating the accessible conformational space of a ligand56,57. One of the earlier
approaches involved was systematic search58. However, the search becomes more and
more complex with the ligand flexibility as the number of degree of freedom of the
ligand molecule increases. Such an approach was implemented in methods where ligand
and binding pocket were considered to be rigid and ligand was fitted using shape
complementarity via point complementarity or distance geometry approaches59,60. In such
docking methods, the shape of both the receptor site and the ligand is investigated based
on shape and pharmacophoric points. Orientations are generated through various
alignment procedures in order to maximize the pharmacophoric constraints and shape
complementarity. However, it is not feasible to exhaustively explore the available
conformational space and a right balance between speed and accuracy has to be made so
that as many binding modes as possible are explored. Fragment-based approaches that
work by either incremental construction of ligand in the binding pocket or just by placing
and joining the fragment circumvent the problem of combinatorial explosion of generated
conformers in the previous approaches61-63.

Stochastic methods involving random sampling of conformational space of ligand in the
binding pocket have also been widely applied in many docking algorithms55. Algorithms
using Monte Carlo sampling coupled with Metropolis criterion are applied to
exhaustively search the conformational space64. Simulated annealing protocol combined
with grid-based energy evaluation can be coupled with this approach to overcome high
conformational energy barrier in conformational sampling65. Another such stochastic
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approach that has been successfully implemented in docking algorithm is the genetic
algorithm based sampling of conformational space66-68. In this approach, multiconformers referred as chromosomes are evaluated, crossed and mutated and the best
possible solution is kept based on the fitness function. The solution is represented by the
best scored conformation of the total conformers after a set number of generations.
GOLD (Genetic Optimization for Ligand Docking) is the most applied and well known
for flexible molecular docking69.

In contrast to these systematic and stochastic approaches, molecular dynamics-based and
heuristic tabu searches have been implemented to explore the sample space56,70,71.
However, molecular dynamics is computationally expensive which has restricted its use
in docking. To circumvent this exhaustive sampling, tabu search approaches were
adopted where a list of already explored conformations were maintained and only
unexplored spaces were sampled72. This avoids reinvestigating the space already sampled
by associating the sampled conformations with a degree of penalty. Apart from these
deterministic approaches hybrid consensus approaches have also been implemented that
combine features from other two approaches73,74. Although these approaches can
exhaustively and successfully sample and generate all the possible conformations within
the active site, the success of any docking program depends on how well it can reproduce
the experimental binding mode of ligand within the cavity. The idea is to successfully
predict the most energetically favorable pose out of thousands of sampled conformers.
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1.2.4 Scoring
The success of whole molecule docking, de novo construction of molecules into a target
site, or screening large virtual combinatorial libraries is ultimately dependent on the
accuracy of the scoring function that ranks the compounds. Ligand orientations can be
evaluated on the fly as the ligand or fragment is positioned within the cavity or all the
generated poses can be scored in the end. The scoring methods that are used in highthroughput settings dealing with thousands of diverse compounds can be evaluated by
how well the corresponding relative binding affinities can be predicted. This need has led
to the development of a wide variety of methods, which can be subdivided in four major
approaches: force field-based methods, semi-empirical approaches, empirical scoring
methods, knowledge-based potentials and lastly consensus scoring functions that are
combination of multiple scoring functions55,75.

Force field-based scoring methods generally use a molecular mechanics force field,
which contains terms for intramolecular forces like bond, angle and dihedral terms
between the atoms that are bonded to each other plus energy terms for intermolecular
forces that describes the forces between non-bonded atoms such as van der Waals and
Coulombic terms. There are a number of widely applied and successful molecular
mechanics-based scoring functions76-79. Due to their simplicity, they are widely applied
and suitable for use in virtual screening. Though faster and simpler, they are ideally not
meant for simulating biomolecular interactions as these methods were developed for
calculating gas phase enthalpy of binding. However, this class of scoring approach is
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associated with many drawbacks and does not account for hydrophobic interactions,
solvation and entropic effects.

Empirical scoring methods offer an alternative approach to pure molecular mechanicsbased force field methods for scoring80. The underlying idea is that the binding free
energy of a non-covalent protein-ligand complex can be factorized into a sum of
localized and chemically intuitive interactions. The terms accounting for different
contributions such as hydrogen bonds, hydrophobic interactions, entropic effects are
normalized by weighting factors derived from regression analysis of the data from
training sets comprised of well characterized protein-ligand complexes. Based on the
assumption of additivity, the binding affinity is estimated as a sum of interactions
multiplied by weighting factors and solved by equation of the type (1).

ΔGbinding ≈ ∑ ΔGifi (rl, rp)

(1)

Where fi is a simple geometrical function of the ligand (rl) and receptor (rp) coordinates55.
However, accuracy of these methods depends upon the quality of the experimental
binding data and crystallographic structural data of the training set.

Semi-empirical scoring functions, however, combine the above two approaches and
incorporates empirical or empirically calibrated energetic terms for interactions that
cannot be computed by pure molecular mechanics-based methods. Thus, implicit binding
energy terms such as hydrogen bonding, solvent effects, hydrophobicity and entropic
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terms can be included in the scoring functions. In contrast to force field-based scoring
functions, semi-empirical scoring terms can more accurately estimate the binding energy
by including entropic and solvation effects that are known to significantly affect
biological interactions in aqueous medium81-84.

Knowledge-based scoring functions85 are rule-based scoring functions where rules are
derived from the analysis of structural data of known and well characterized receptorligand interactions. Exponential growth and availability of structural data on proteinligand complexes has allowed deriving and formulating set of rules based on the
frequency of interactions. Scoring functions of this type try to capture the knowledge
about protein-ligand binding that is implicitly stored in the protein data bank by means of
statistical analysis of structural data. The potentials are obtained by statistical analysis of
atom-pairing frequencies observed in crystal structures of protein-ligand complexes86.
However, the accuracy of knowledge-based scoring function depends on the quality of
experimental data, as it incorporates structural knowledge without referring to
inconsistency in experimental and structural data.

Though several approaches have been implemented in deriving a robust scoring function,
none of the scoring functions are ideal, as a variety of approximations are made to make a
compromise between speed and accuracy. Taking into consideration the limitations of a
single scoring function, the concept of consensus scoring evolved based on the premise
that combination of different scoring functions would probably lead to a better
performance by overcoming inherent weaknesses in individual functions87. A consensus
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between a set of scoring functions can be reached either by averaging the rank assigned
by each scoring function or averaging the score value calculated by different functions.
Although a number of scoring functions as well as their combinations have been
implemented, ideally, the best scoring function should be able to discriminate between
native and non-native binding modes and be able to calculate the actual free energy of
binding.

1.2.5 Free Energy Prediction
Predicting the structure and binding affinity of ligand-receptor complex is a challenging
process and forms an integral part of structure-based drug design protocol. Ligand
binding is governed by kinetic and thermodynamic principles. The quantity of interest in
determining binding constants is the free energy difference between the complexed and
uncomplexed state.

ΔGbinding = ΔGcomplex – ΔGfree

(2)

The free energy is measured with the Gibbs free energy (G) of the system. The standard
free energy change of the ligand-receptor binding process can be expressed as ΔGº. The
most common measurement for ΔG is through the equilibrium constant for the complex.

ΔGbinding = -RT ln Keq = RT ln Kd
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(3)

Where R is the gas constant, T is the absolute temperature in Kelvin. Since the
equilibrium constant (Keq) or dissociation constant (Kd) is a direct measure of ligand
affinity; calculation of ΔG, the free energy of binding is of great interest in drug design.
Computationally, the goal is to estimate binding free energy, ΔGbinding, which can be
directly related to the experimentally measured association constant (Ka). A useful way to
consider the binding free energy is in terms of the changes in enthalpy and entropy on
formation of complex, as expressed by the following equation:

ΔGbinding = ΔH- TΔS

(4)

Enthalpic (ΔH) and entropic (ΔS) factors that contribute to ligand binding include the
hydrophobic effect, van der Waal and dispersion interactions, hydrogen bonding, other
electrostatic interactions and solvation effects.

During the complex formation, both receptor binding site and the ligand become partially
desolvated and there is structural reorganization of solvent molecules between the
receptor and ligand. In a majority of cases the solvent molecules are displaced between
receptor and ligand thereby replacing existing hydrogen bonds between solvent and
receptor or ligand. Also there is a change in entropy on binding as it is accompanied by
change in translational and rotational degrees of freedom for the ligand, receptor and
solvent molecules. In order to calculate the binding energy accurately, the scoring
function should include all the enthalpic and entropic terms. So far, there are a wide
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variety of different techniques available for predicting the free energy of protein-ligand
binding, but most scoring functions do not include all of these terms27,28,54,88.

Most of the functions are based on the assumption that different contributions to free
energy of binding are additive and can be calculated separately. The free energy of
binding can be partitioned and calculated as an additive contribution from different parts.
The “master equation” can be written as:

ΔGbinding = ΔGsolvent + ΔGconf + ΔGint + ΔGmotion

(5)

Where, ΔGsolvent is the free energy contributions from the solvation or hydration free
energy, ΔGconf is due to conformational changes in the protein and ligand, ΔGint is free
energy due to specific protein-ligand complex as a result of their proximity and ΔGmotion
is free energy as a function of motion of receptor and ligand89.

Ideally, all the energy contributions should be ensemble averages as the complex, the free
protein, and the ligand are dynamic entities and these free energies can be calculated by
integrating over all possible configurations of the protein, ligand and solvent system. Free
energy perturbation methods allow direct calculations of certain differences in free
energies90. The basic idea of free energy perturbation is derived from statistical
mechanics as it relates the free energy of a system and ensemble average of an energy
function that describes the system. However, free energy perturbation still requires
relatively large amounts of computer time, provides very limited conformational
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searching and remains technically difficult. Consequently, most approaches use
approximate methods54,89.

The force-fields used for calculations of free energy and intermolecular interactions
assume that steric and electrostatic forces are sufficient to account for the observed
biological interactions. However, these alone are never sufficient in accurate prediction
of biomolecular interactions as they do not always include solvation/desolvation effects.
The entropic contributions to binding are much less well-defined and often poorly
quantitated or even ignored in most of the cases. Most approaches sum up these
interactions separately as distinct enthalpic and entropic contributions, whereas, in
reality, the ligand-protein recognition is a concerted event and thermodynamic quantities
cannot be just simply summed.

1.3 HINT Model
This work focuses on an alternative force field-based on the experimental information
from log Po/w (partitioning coefficient for water/1-octanol). Since log Po/w is an
experimentally derived thermodynamic quantity, it directly correlates with the free
energy of interaction and encodes all non-covalent interactions in the biological
environment as well as solvent effects and entropy91,92. The HINT model describes
specific atom–atom interactions between two molecules, using the equation:

HTOT = ∑∑ bij = ∑∑ (aiSi ajSjRijTij + rij)
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(6)

where a is the hydrophobic atom constant (derived from log Po/w), S is the solvent
accessible surface area, T is a function that differentiates polar – polar interactions (acid –
acid, acid – base or base – base), and R and r are functions of the distance between atoms
i and j . The interaction score bij describes the specific atom–atom interaction between
atoms i and j, and HTOT represents the total HINT interaction score. The HINT model is
based on the assumption that each bij approximates a partial δg value for a specific atom–
atom interaction, thus the total HINT score, which is the cumulative sum of all the atom–
atom interactions, correlates with ΔGinteraction, i.e., ΔG = ∑(δG). The HINT paradigm has
been extensively applied for predicting the free energy of binding for protein –ligand and
other systems91,93-95.

1.3.1 HINT Hypothesis
Hydropathic interactions comprising of polar and hydrophobic interactions form the very
foundation of intra and intermolecular interactions. Although polar interactions can be
accurately quantified using quantum chemistry methods, hydrophobic interactions are
hard to quantify. The thermodynamic factors which give rise to the hydrophobic effect
are complex and still incompletely understood. The hydrophobic effect is considered to
be the major driving force in protein folding resulting in the burial of the hydrophobic
residues in the core of the protein. It is exemplified by the fact that oil and water do not
mix and oil droplets coalesce together to form a separate layer. The Hydrophobic effect,
which is considered to be mainly entropy driven, is also responsible for protein-ligand
interaction and bio-macromolecular association. However, commonly used molecular
mechanics-based forcefields do not include terms for quantifying entropic energy. There
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are, however, computationally intensive free energy perturbation methods that are able to
accurately calculate free energy of binding90,96.

The HINT forcefield is based on empirically-derived Log Po/w values that intuitively
estimate free energy of binding, ΔG96. Log Po/w is a thermodynamic quantity that encodes
both enthalpic and entropic term. These include hydrogen-bonding, acid-base
interactions, coulombic attractions as well as hydrophobic interactions. All of these are
related to solvent partitioning phenomena and the free energy of transfer of a compound
from one reference state, such as an organic solution, into water, involves free energy
change comprised of enthalpic and entropic contributions. The two phases, i.e., octanol
and water, correspond to hydrophobic and polar residues and also are analogous to the
hydrophobic microenvironment inside the binding cavity and solvent system. Since the
dissolution of any compound in a mixed solvent system involves the same fundamental
processes as biomolecular interactions within or between proteins and ligands, HINT
derives the information from bulk molecular solvent partitioning to discrete interactions
between the atoms. The program calculates empirical atom-based hydropathic parameters
(hydropathic atom constant) that encode all significant intermolecular and intramolecular
non-covalent interactions implicated in drug binding or protein folding. The hydropathic
atom constant forms the core of HINT paradigm.

The hydrophobic atom constant, a, is the key parameter in the HINT model. The atom
constant, a, is calculated using an adaptation of the hydrophobic fragment constant
approach of Hansch and Leo97. However, contrary to the Hansch and Leo approach, that
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calculates the total solvent partition constant for a molecule by summing up the fragment
constants, HINT backtracks from this point and distributes and assign atom constant to
each atom of a fragment or molecule. Facilitating this are two databases for small
molecules and bio-macromolecules, with re-parameterized force-field atom types,
modified factors for bond, ring, and branched chain fragment data. The molecular
database is used for structure/connection based calculation of Log P. The database
contains a data tree of partition information and a bare hydrophobic atom constant for
each atom type. These bare hydrophobic atom constant values can be modified by a
variety of factors specific to the molecular environment. A series of simple rules based on
atom connectivity and proximity to other atoms identify and apply these modification
factors to atom constants. In case of bio-macromolecules, dictionary-based calculations
are carried out for log P depending upon the acidic, basic or neutral solvent condition
where the modification rules are implicitly applied. Hydrogen atoms can be treated
explicitly to model interactions more accurately. These modification factors characterize
actual biophysical phenomena related to the molecular structure and properties. These
hydrophobic atom constants along with modification factors encode the thermodynamic
information and reveal the potential type and strength of interaction that the atom may
encounter. Coulombic, hydrogen bonding, dispersion as well as hydrophobic effects may
be extracted from the hydrophobic atom constant by examination of the sign and
magnitude of the constant.
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1.3.2 HINT Calculation
The basic principle and application of HINT methodology is calculation of experimental,
information-rich hydropathic atom constants and calculation of atom-atom interactions in
a bio-molecular system. The partition constant LogP is a thermodynamic parameter,
which due to its unprocessed and unbiased experimental nature, contains interaction
information specific to the biological environment as well as solvent effects and
entropy98,99. HINT was created specifically to calculate all non-covalent interactions. In
practice, the conceptually simple HINT model scores each atom–atom interaction within
or between biological molecules according to equation (6). As mentioned bij is the
interaction score between atoms i and j, a is the hydrophobic atom constant, S is the
solvent accessible surface area (H2O probe), Tij is a logic function describing acid-acid,
acid-base and base-base interaction, and Rij and rij are functions of the distance between
atoms i and j (i.e. r). Generally the hydropathic-dependent function, Rij, is the simple
exponential e–r and rij is an implementation of the Lennard- Jones potential function. The
rij term is mostly a penalty function to prevent van der Waals violations. The double sum,
∑∑bij, is the total interaction score for the system. The HINT convention is that favorable
interactions are scored with bij > 0 and unfavorable interactions are scored with bij < 0.
The logic function Tij returns a value of 1 or –1 depending on the character of the
interacting polar atoms (i.e. a < 0): there are three possibilities: acid–acid, acid–base, or
base–base; only acid–base is scored favourably. Since polar moieties are markedly
differentiated from hydrophobic moieties, the explicit interactions between a ligand and
its receptor can be predicted. Besides this, the general microenvironment of the binding
site can also be characterized. Likewise, and more exciting, complementary binding
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points within the binding pocket can also be derived, giving a deep insight as to what an
ideal ligand would look like. The HINT forcefield and its free energy scoring functions
have been extensively applied and validated and have shown to be useful in a wide
variety of biomolecular simulations93,100-102. To further extend the capability and
applicability of HINT program, all the algorithms have been incorporated in a toolkit103.

1.4 Amalgamation of Experimental and Theoretical
Approaches: Scope and Limitations
The field of molecular modeling lies at the interface of experimental and theoretical
approaches. Computational modeling techniques attempt to simulate an abstract model of
a particular system and are often plagued by very drastic approximations. The problem is
further compounded by inherent experimental errors and artifacts. While, structural data
available from x-ray crystallography and NMR has undeniably encouraged the efforts
towards understanding the structure and functions of protein, only partial agreement
between experimental and theoretical data has been observed based on these crystal
structures. Often the issue raised is how representative is a single crystal structure in a
structure-based drug design project? In addition to the obvious correlation between
crystal structure resolution and accuracy, there are other considerations such as the
reliability of place water molecules and thermal motion of unconstrained residues. By
and large it has been difficult to correlate solution binding data, crystallographic
structural data with theoretical calculations. The main reason for this inconsistency could
be attributed to inherent experimental constraints. The binding data is generally not of a
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quality to enable accurate quantitative comparisons. Some spectroscopic experiments can
give direct measurement of free energy while calorimetric experiments just yields the
enthalpic or heat energy changes of system. In addition to this, ∆G computed via
sophisticated simulations often do not correlate well with the experimental binding
measurements as quite often computational chemists involved in pharmaceutical research
interchangeably use Ki and IC50 with Kd data in calculation of free energy relationships. It
is commonly becoming a practice in drug discovery community to have assays that
generate IC50 values rather than equilibrium constants. These approximations severely
undermine the accuracy of models and should be used with discretion.

One of the main aims in structure based drug design is explaining the binding interactions
between a drug and its target. This is often achieved by virtual screening, more
specifically, identifying a lead molecule out of thousands of molecules by docking and
predicting affinity against a target protein. There are number of issues that currently are
not adequately addressed. For example, in such calculations enthalpic contributions are
often estimated by theoretical methods, knowledge-based potential functions, or
parameters derived from experimental data. The force-fields used for calculations of free
energy and intermolecular interactions assume that steric and electrostatic forces are
sufficient to account for the observed biological interactions. However, these alone are
never sufficient in accurate prediction of biomolecular interactions as they do not always
include solvation/desolvation effects. The phenomenon of solvation/desolvation within
the protein active site resulting in hydrophobic interactions has been particularly difficult
to model computationally. Besides this, appropriate consideration of ionization and
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tautomerization state of ligand and protein is also very important. Assumption of
structural rigidity as an approximation may have severe entropic repercussions. In
addition, binding may lead to protein adaptability and additional conformational changes
that are not normally considered. These entropic contributions to binding are much less
well-defined and often poorly quantitated or even ignored in many cases. Most
approaches sum up these interactions separately as distinct enthalpic and entropic
contributions, whereas, in reality, the ligand-protein recognition is a concerted event and
thermodynamic quantities cannot be just simply summed. The interaction energies
calculated without entropic contributions are not always expected to correlate well with
the measured free energies of binding. Virtual screening has limited accuracy in
exchange for a list of few promising candidates for further evaluation.

Pioneering studies in free energy calculation over the past few years have made
significant progress towards this goal. Among the several methods available to calculate
free energy, complex and time consuming molecular dynamics simulations with explicit
water have been shown to correlate with free energy. Free energy perturbation (FEP)
calculations based on statistical mechanics relates the free energy of a system calculating
the ensemble averages and treating solvent molecules and ions explicitly. However,
calculation of free energy using molecular dynamics simulation is plagued by errors from
a variety of sources. Statistical errors arise from the limited sampling of configurations
accompanied by errors arising from the imperfect equilibration of the system. Multiple
levels of time and uncertainty are compounded for complex biomolecular systems with
inclusion of solvents and counter ions.

However, the size of the system makes
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approaches of this sort computationally expensive and so simplified models are generally
applied.

Though computational modeling techniques hold a great promise for future progress in
drug discovery and development it is still an evolving technology and has number of
limitations. However the tools and techniques should be used with great cautions. Any
theoretical model generated should be validated with experimental methods.

1.5 Research Plan
A new methodology based on HINT paradigm94 is applied to design novel inhibitors of
tubulin protein and predict the binding mode of the protein-ligand complexes. The
research utilizes the biological data, correlated with structure, to optimize the current (and
succeeding) drug leads to design more effective candidate compounds with improved
efficacy and minimal toxicity. The study also aims towards developing novel molecular
modeling tools to design clinically viable molecules.

Given the utility of microtubule targeting as a strategy in the treatment of malignancy, the
design and development of a new and clinically active class of microtubule-targeting
compounds is highly desired. Pyrrole containing molecules derived from nature have
proven to be particularly useful as lead compounds for drug development104,105. Highly
functionalized pyrroles have previously been demonstrated to have potent cytotoxicity
against a variety of human tumors with activity expressed at nM and µM concentrations
in human breast tumor cell lines106,107. Collaborators in this research have recently
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developed a series of brominated pyrroles, whose structure suggests that they might
interfere with tubulin function (Figure 1a, b). Both cellular studies with one of the
compounds, JG-03-14 (3,5-dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic
acid ethyl ester) and molecular modeling analysis tend to support the contention that
these compounds function as microtubule poisons108. As described later, the development
of additional synthetic or semi-synthetic pyrrole derivatives is greatly facilitated due to
their relative ease of synthesis, which, in turn, facilitates manipulation of the molecular
properties in adding and removing a broad range of functional groups109. Consequently,
this research proposes to refine and develop pyrrole-containing alkaloids as new
chemotherapeutic agents for the treatment of breast cancer.

1.5.1 Preliminary Research/Data
In the initial studies carried out by our collaborators, several substituted pyrroles (Figure
1b) were evaluated for their inhibitory activity on the growth of MCF-7 breast tumor
cells108. The studies demonstrated that the highest degree of anti-proliferative activity
was expressed by JG-03-14, while a lesser degree of activity was evident for compound
JG-05-2. The other analogs examined failed to demonstrate significant anti-proliferative
activity at concentrations up to 500 nM.

34

Figure 1: a) Highly functionalized pyrrole scaffold. b) Structure of substituted pyrroles.
a)

Y

X

A

N
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These observations provided insight into the structural requirements for the growth
inhibitory activity/cytotoxicity of this class of agents and offer significant opportunity for
structural alterations, which could lead to an improved drug candidate. All the subsequent
experimental studies conducted by our collaborators suggested that JG-03-14 promoted
extensive cell death during the initial period of exposure. These observations indicated
that JG-03-14 abrogates breast tumor cell growth and survival through both the
promotion of autophagic cell death and induction of a permanent growth arrested state.
COMPARE analysis across NCI cancer cell line panel evaluated similar activity profile
of colchicine and JG-03-14 and further corroborated mechanism of action of JG-03-14 to
be similar to that of colchicine. Thus, there is strong evidence that this class of
compounds interferes with the microtubule function. The effects of JG-03-14 along with
the two positive controls, combretastatin A-4 and thiocolchicine, on tubulin assembly
were studied (Table 1). All these agents inhibited the assembly of tubulin.

Examination of the initial docking model in detail illustrates (Figure 2), the pocket shape
and size, as indicated by the green translucent surface. The occupancy of the JG-03-14
compound in this pocket is shown by the dot surface (color coded by brown=lipophilic,
green=polar), regions of the site that do not have optimum interactions and consequently,
locations at which molecular modifications of the lead compound might be effective, can
be seen.

For example, the left region of the pocket, which is quite hydrophobic,

effectively accommodates the two methoxy group substituents to the aromatic ring of JG03-14, but may be able to tolerate more steric bulk.
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Table 1: JG-03-14 inhibits tubulin assembly and [3H]colchicine binding to tubulin.
The effects of JG-03-14, and the positive controls combretastatin A-4 and thiocolchicine,
on tubulin assembly were studied. All these agents inhibited the assembly of tubulin and
the EC50 values for inhibition (at 10 µM tubulin) were calculated. The effects of these
compounds on 5 µM [3H]colchicine binding to 1 µM tubulin were determined. ND =not
determined.
Inhibition of tubulin assembly (EC50 in μM)
JG-03-14
Combretastatin A-4
Thiocolchicine

1.5 ± 0.2
1.3 ± 0.1
1.0 ± 0.1
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% Inhibition of binding by inhibitor at
1 μM
5 μM
49 ± 3
84 ± 0.6
83 ± 2
97 ± 2
ND
67 ± 0.07

Figure 2: Difference between pocket (green surface) and JG-03-14 structure volumes
indicates regions of interest for designing new active analogs.
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This model also suggests that the pyrrole substituent α to the nitrogen [C(=O)OCH2CH3
in JG-03-14] can be optimized to make better interactions with the residues at the
entrance to the pocket. Highly selective novel analogs with minimal toxicity can be
designed using the proposed HINT-based de novo design methodology. The primary aim
of this research is to design a library of highly selective pyrrole-based analogues. The
fragment-based approach can, therefore, be considered as a good working hypothesis for
rationally designing novel analogs since the individual building blocks have to be linked
in order to be a meaningful inhibitor. If the individual building blocks can be chemically
linked easily in a chemical fashion, the approach has the advantage that the building
blocks can be synthesized separately and linked in the final stage of the synthesis.

A very extensive library of compounds for the synthesis and evaluation of analogs of JG03-14 can be created using fragment-based methodology. The rationale is to select the
compounds which have demonstrated interesting bioactivity, and vary the A, B, X, Y and
Z groups (Figure 1a) in a logical manner based on modeling studies and the use of
standard QSAR considerations (lipophilic character, electronic effects and steric effects).
Each of the target molecules can then be subsequently subjected to docking and QSAR
evaluation prior to the synthesis. Structure activity information from other known agents,
which have similar binding properties, can also be incorporated into the selection of the
indicated target molecules. This study also appreciates the fact that the most active
compound found may not be the ideal candidate due to toxicity effects on normal cells. It
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serves little purpose for a drug to kill tumor cells if overall toxicity to host tissue is high
(i.e., the drug has low selectivity and/or a narrow therapeutic index. One of the objectives
of this research was to design novel analogues using structure-based/ligand based
computational methods. This is only the starting point for one of several approaches to be
explored as predictive tools for molecular design. Therefore, this methodology will allow
generation of a large family of strong candidates, on which, further xenograft and clinical
studies can be carried out.

Another such attempt was carried out to design and develop novel stilbene analogs that
also target the microtubules at the colchicine site and act as anti-leukemic agents. A
series of novel stilbene derivatives have been synthesized and studied with the main goal
to investigate SAR of the stilbene analogs, as well as to improve its water solubility, a
potentially negative aspect of this molecule that could be a serious hindrance in the preclinical development. We attempted to optimize stilbene 5C using computer-based drug
design and synthesize derivatives with benzimidazole or indole group. Derivatives with
good cytotoxic activity, in particular, the derivatives 5C and 6C (Figure 3) were obtained
and the study gave rise to two novel leads for further investigation. Alternative approach
was also adopted to make prodrugs of stilbene 5C. A morpholino-carbamate derivative,
prodrug of 5C, has a very good solubility in water, and is active in suppressing growth of
tumor cells at a concentration of 5000 nM, which is a concentration 100 times higher than
the parent stilbene 5C.
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Figure 3: Stilbene 5C and 6C.
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These data suggest that stilbene analogs could be a good candidate for further preclinical and clinical development as a new anti-tumor agent for cancer therapy.

A second synergistic, goal of this research was to design and develop novel molecular
modeling software tools that would de novo identify and characterize the binding site and
design analogs within the binding site. The available crystal structure of tubulin protein
has a low resolution of 3.58 Å, undermining the ability to design highly selective ligands.
Target-based generation of lead compounds requires that the three-dimensional structure
of the ligand binding site be known as accurately as possible. Identification and
characterization of active sites is imperative in the study of protein structure, particularly
for the design of molecules that interfere with its function and modulate activity.
However, in a low resolution crystal structure model, knowledge about the correct
orientation of side chains is limited by ambiguities in position and orientation because the
experimental electron density envelopes are generally featureless. Through the
computational modeling studies, it was intended to elucidate the binding process by
better characterizing the binding site.

This involved analyzing the hydropathic character of the binding site and generating
synthetically viable functionalities on parent molecules to exactly complement the
binding features in the active site. This feature effectively facilitated designing clinically
viable drug candidate with minimal toxicity. The methodology can also be extended to
other systems and may find extensive applications in de novo drug design projects. These
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efforts are expected to give rise to a new class of selective and potent anti-tumor drugs
for use in combination chemotherapy.

1.5.2 Expectations, Interpretation and Impact
A key success criterion for this research is to productively use the biological cytotoxicity
data to design new and more potent analogs. Development and biological evaluation of
diverse set of analogs will be accomplished by the collaborators. The synthetic
methodology used by our collaborators is very flexible and rapid, making it possible to
synthesize and test many compounds designed computationally and thus, allow
significant diversity in pyrrole substituents. This research plans appropriate SAR
(Structure Activity Relationship) guided structural alterations on the lead compounds to
optimize the desired bioactivity and minimize toxicity. This will involve structural
changes, which will probe steric, electronic and lipophilic character of the parent
molecule. Once the targeted compounds are prepared, sensitivity will be compared in
breast tumor cells and normal cells.

Favorable findings in terms of new compounds based on this research design would
guide the synthetic efforts to develop analogs with a higher degree of selectivity. The
success of this research project depends on the effectiveness of the multidisciplinary
collaboration. For example, cytotoxicity studies will allow molecular models and QSAR
approaches to be refined, which will then suggest the next round of pyrrole analogs to be
synthesized and biologically evaluated with the ultimate goal of generating a significant
clinical candidate.
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The iterative cycles of modelingÆsynthesisÆtestingÆmodeling, etc. will be
continuously monitored to improve the models and consequently, the predictions of the
compound activities.
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CHAPTER 2
Docking and Hydropathic Scoring of Polysubstituted Pyrrole
Compounds with Anti-Tubulin Activity

2.0 Abstract
Compounds that bind at the colchicine site of tubulin have drawn considerable attention
with studies indicating that these agents suppress microtubule dynamics and inhibit
tubulin polymerization. Data for eighteen polysubstituted pyrrole compounds are
reported, including antiproliferative activity against human MDA-MB-435 cells and
calculated free energies of binding following docking the compounds into models of αβtubulin. These docking calculations coupled with HINT interaction analyses are able to
represent the complex structures and the binding modes of inhibitors such that calculated
and measured free energies of binding correlate with an r2 of 0.76. Structural analysis of
the binding pocket identifies important intermolecular contacts that mediate binding. As
seen experimentally, the complex with JG-03-14 (3,5-dibromo-4-(3,4-dimethoxyphenyl)1H-pyrrole-2-carboxylic acid ethyl ester) is the most stable. These results illuminate the
binding process and should be valuable in the design of new pyrrole-based colchicine site
inhibitors as these compounds have very accessible syntheses.
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2.1 Introduction
A large number of targets are under exploration for chemotherapeutic treatments for
cancer. In the past several years, based on the efficacy and commercial successes of
paclitaxel and the vinca alkaloids, there have been major efforts to design inhibitors that
bind and interfere with the function of microtubules. Microtubules are essential elements
of the cytoskeleton and extremely important in mitosis and cell division. Colchicine, the
first drug known to bind to the tubulin protein110,111, inhibits microtubule formation and at
high concentrations causes loss of cellular microtubules. In contrast, paclitaxel and its
analogues actually promote microtubule polymer formation112-114, albeit by acting at a
different site on tubulin than colchicine. A variety of small molecules with diverse
molecular scaffolds have been shown to bind tubulin at the colchicine site115-118. One
class of these compounds receiving particular attention has been that based on the natural
product combretastatin A-4 discovered by Pettit119,120.

Despite some successes, the

discovery of new, more efficacious inhibitors is becoming increasingly important because
of multi-drug resistance to tubulin-binding antimitotic agents121.

Natural products containing pyrrole have diverse and interesting biological activities, and
have proven to be particularly useful as lead compounds for drug development105,109,122.
As part of long-term program to develop vinylogous iminum salt-based syntheses of
natural products containing the pyrrole group, some early synthetic intermediates were
evaluated against a panel of human and murine tumor cell lines123. Many of these
synthetic compounds were highly active against cancer cell lines, and some inhibited
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DNA synthesis without binding directly to DNA124. Earlier studies also provided clues to
the design of pyrrole analogs that might have potent antiproliferative activities and the
ability to bind to tubulin.

The marine natural product lukianol A contains a highly oxygenated 3,4-diphenylpyrrole
motif, and it potently inhibited the growth of the human KB cancer cell line125. Banwell
and colleagues suggested that lukianol A represented a configurationally stable hybrid of
combretastatin A-4 and colchicine126. John Gupton from University of Richmond has
synthesized another class of biologically interesting pyrroles, which are somewhat related
to the pyrrolomycin natural products by virtue of their halogenated pyrrole backbone127.
Brominated analogs of previously synthesized pyrroles were prepared, and they retained
the cytotoxic activity exhibited by the non-brominated pyrroles128. While mechanistic
studies indicated that two of the brominated pyrrole compounds bound directly to DNA,
causing DNA cross-linking, the mechanisms of action of other brominated pyrrole
analogs remained unknown. Based on the structural similarity of the compounds to
combretastatin A-4 and Banwell’s suggestion that several pyrrole containing natural
products represent stable hybrids of combretastatin and colchicine, the effect of
brominated pyrroles were examined on cellular microtubules. Several of the brominated
pyrrole analogs had microtubule depolymerizing effects. The most potent was 3,5dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid ethyl ester (JG-03-14;
structure in Figure 4).
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Figure 4: Substituted Pyrroles
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It is significant to note that JG-03-14 is structurally unique among combretastatin-like
compounds. It possesses a single phenyl group which is highly oxygenated; other
combretastatin analogs always possess two highly oxygenated phenyl groups. The mode
of action and the cellular effects of this compound were evaluated in detail, and it was
found to be a potent antimitotic agent. Binding studies show that JG-03-14 binds to
tubulin within the colchicine site. Our initial studies indicate that this compound has
antitumor effects and it represents a promising lead for the generation of new analogs
with important biological properties. While investigating the cytotoxic activity of
compounds in a series of synthetic polysubstituted pyrroles (Figure 4), our interest in the
colchicine binding site of tubulin as a putative target for computational drug design
studies was piqued after a COMPARE129 analysis showed a correlation between one of
the compounds (JG-03-14) and colchicine of 0.681 over the 45 cell lines that were
assayed for both compounds. COMPARE evaluates similarities in activity profiles across
the NCI cancer cell line panel, and has been used to elucidate modes of action for new
anticancer agents129. COMPARE analysis and modeling studies suggest that JG-03-14
represents a novel chemotype for the colchicine site. However, in any case, the true
therapeutic potential of the colchicine site on tubulin has not been fully explored because
of the lack of truly atomic level knowledge of the site.

In 2000, Hamel and colleagues mapped the binding site of colchicinoids on β-tubulin130.
Using molecular modeling and computational docking of colchicinoids into the electron
crystallographic model of β-tubulin in protofilaments130, they found two potential binding
sites. The first was entirely encompassed within β-tubulin with the colchicinoids forming

49

adducts with Cys 356. The second potential site was located at the α/β interface and
involved hydrogen bonding with Cys 241. More recently, Nguyen and colleagues131
developed a comprehensive pharmacophore model for structurally diverse colchicine-like
tubulin inhibitors using a structure-based approach on the newly available α/βtubulin:DAMA-colchicine X-ray structure132.

This crystal structure definitively

identified a cleft at the α/β interface as the colchicine binding site, but has a resolution of
only 3.58 Å and thus requires considerable computational effort before models derived
from it can be considered “all-atom”.

In this chapter we report the results of docking this set of putative ligands into the
colchicine site of tubulin to build stereochemically reasonable models. We evaluated
these docking models with the HINT free energy force field91 and found a good
correlation between HINT scores and measured IC50s of cell proliferation by the
compounds. While the measured IC50s represent a downstream biological effect and we
are making the pragmatic assumption that the modes of action for all compounds in this
series are the same, these results do allow us to appropriately characterize the colchicine
binding site and will also serve in design and validation of new compounds similar to JG03-14 in later stages of this research. This is particularly relevant since these and other
polysubstituted pyrrole compounds are synthetically accessible.
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2.2 Materials and Methods
2.2.1 Synthesis of Pyrrole Compounds
The synthetic methods used to prepare the highly functionalized pyrroles and related
derivatives depicted in Figure 4 can be found in previously reported work128,133-136.

2.2.2 Antiproliferative Activity of Substituted Pyrroles against Human
Tumor Cell Lines
The antiproliferative effects of the compounds were evaluated in MDA-MB-435 cells
using the SRB assay as previously described137. All the biological assays were carried out
by Dr. Susan L. Mooberry and colleagues at SFBR. A 48 hr exposure time was used.
The IC50 values, i.e., the concentration that causes 50% inhibition of proliferation, was
calculated from the log dose-response curves and represents the mean of three
independent experiments. The effects of the compounds on cellular microtubules were
evaluated using indirect immunofluorescence techniques.

Briefly, A-10 cells were

exposed to the compounds for 18 hr and then the cells were fixed and microtubules
visualized using a β-tubulin antibody and the DNA was visualized using DAPI. The
EC50s for microtubule depolymerization were determined using visual observation as
previously described138. A range of concentrations was tested for each compound and the
percent microtubule loss determined for each concentration.

The data from 3

independent experiments were averaged and plotted as percent microtubule loss vs.
concentration and EC50 values calculated.
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2.2.3 Model Building
The X-ray crystal structure (3.58 Å) of αβ-tubulin complexed with DAMA-colchicine132
PDB code: 1SA0) was used in this study. The stathmin-like domain and the C and D
subunits were removed from the model. After hydrogen atoms were added to the model,
their positions were optimized to an energy gradient of 0.005 kcal-Å/mol with the Tripos
force field (in Sybyl 7.1) while keeping heavy atom positions fixed. The models for
pyrrole analogues were constructed using the Sybyl 7.3 (www.tripos.com) suite and
optimized similarly78.

2.2.4 Docking
Computational docking was carried out using the genetic algorithm-based ligand docking
program GOLD 3.069. GOLD explores ligand conformations fairly exhaustively and also
provides limited flexibility to protein side chains with hydroxyl groups by reorienting the
hydrogen bond donor and acceptor groups. The GOLD scoring function is based on
favorable conformations found in Cambridge Structural Database and on empirical
results of weak chemical interactions139. The active site was defined by a single solvent
accessible point near the center of the protein active site, an approximate radius of 10 Å,
and the GOLD cavity detection algorithm. GOLD docking was carried out without
constraints to get an unbiased result and to explore all possible binding modes of the
ligands. The tri-methoxy phenyl fragment of colchicine was used as the template for
biasing the pose of all ligands. In this study we performed 100 GOLD genetic algorithm
runs, as opposed to the default of 10 and early termination of ligand docking was
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switched off. All other parameters were the defaults. To evaluate and validate GOLD
performance the co-crystallized ligand DAMA-colchicine132 was extracted and docked.
GOLD accurately reproduced the experimentally observed binding mode of DAMAcolchicine in αβ-tubulin. All remaining ligands were docked using the same parameters.

Dockings with different/optional constraints such as enforced hydrogen bonds,
hydrophobic regions and scaffold match were also explored.

For hydrogen bond

constraints, docking was biased so that the ligands make hydrogen bonds with Asn258,
Ser178, Asn101, and the backbone amides of Ala180 and Val181. For region
hydrophobic constraints the ligand positions were constrained by defining a hydrophobic
sphere where the tri-methoxy phenyl moiety of colchicine was positioned. Then specific
ligand atoms to be docked in the hydrophobic region of the active site were defined.
Alternatively, scaffold match constraints were used to place the ligand at a specific
position within the active site.

2.2.5 Hydropathic Scoring
The HINT (Hydropathic INTeractions) scoring function91 (version 3.11S β) was used to
investigate the structural aspects of the interactions by analyzing and ranking the GOLD
docking solutions. For selection of the optimum docked conformation and to further
differentiate the relative binding efficacy of the pyrrole ligands, interaction scores were
calculated for each pose found by docking. The protein and ligands were partitioned as
distinct molecules. “Essential” hydrogen atoms, i.e., only those attached to polar atoms
(N, O, S, P) were explicitly considered in the model and assigned HINT constants. The
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inferred solvent model, where each residue is partitioned based on its hydrogen count,
was applied. The solvent accessible surface area for the amide nitrogens of the protein
backbone were corrected with the “+20” option. Finally, HINT scores were plotted
against experimental binding free energies that were calculated using the standard Gibbs
free energy equation:

∆Gbinding = - R T ln(Keq),

(7)

where R is Boltzmann’s constant (1.9872 cal K-1 mol-1) and T is 298 K; Keq is an
equilibrium binding constant, ideally KD. In this work measured IC50 values are being
used as approximations for equilibrium constants.

2.3 Results and Discussion
While the character of the colchicine binding site was investigated by Nguyen et al.131,
their study was directed at deriving a generalized pharmacophore for the site and
consequently the data set included only two polysubstituted pyrroles. These compounds
represent an emerging class of agents with potential activity against a variety of human
tumors with activity expressed at nM or µM concentrations in human tumor cell
lines108,135, but having advantages over natural products in terms of drug design and
development. In particular, we have been exploring a series of brominated pyrroles
whose structure suggests that they might interfere with tubulin function. One member of
this series (JG-03-14, 3,5-dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic
acid ethyl ester), for which NCI tumor panel activity had been obtained128, was suggested
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by COMPARE129 to have an activity profile similar to colchicine. Cellular studies with
JG-03-14 further support the contention that these compounds function as microtubule
poisons108. In addition, JG-03-14 was found to promote autophagic cell death while
retaining activity in tumor cells expressing the multidrug resistant pump108,133. Because
the development of additional synthetic or semi-synthetic pyrrole derivatives in this class
is facilitated with their relatively facile syntheses, including modification of the molecule
by adding and removing functional groups128, we have both a rather extensive collection
of molecules in-hand (Figure 4) for building predictive molecular models and the
potential for rational design and synthesis of many others.

2.3.1 Antiproliferative Activity of Polysubstituted Pyrroles
Results from a number of assays have previously appeared regarding the cytotoxic
activities of the lead compound JG-03-14108,128,140. However, most of the compounds in
this series have not been examined in detail. An important component of structureactivity relationships and/or computational activity predictions is having reproducible and
comprehensive data for a relatively large series of compounds, even those with
comparatively poor activity, because understanding why particular compounds are
inactive is potentially just as valuable as data on active compounds. Table 2 sets out the
experimental antiproliferative assay results against human MDA-MB-435 cancer cells for
the compounds in Figure 4. While JG-03-14 remains the compound with the most potent
(36 nM) activity, a few others (Table 2) have activities that are only about 7-10 fold less
potent, thus suggesting that design of additional new compounds with desirable
properties is possible.
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Table 2: Experimental IC50, EC50 and docking results for polysubstituted pyrrole
compounds.
Compound

Activity
Set

IC50 for antia
proliferation

pIC50

ΔGbinding
(kcal mol-1)

HINT
score

HINT
LogP

EC50 for loss of
b
microtubules
490nM

JG-03-14

36 nMc

7.74

-10.14

626

2.60

JG-03-6

312 nM

6.51

-8.87

609

3.17

>50μMf

361 nM

6.44

-8.78

483

2.36

5.1 μM

JG-05-3B

278 nM

6.55

-8.94

410

2.36

2.4 μM

JG-05-5

919 nM

6.04

-8.23

559

3.02

JG-05-8

2.2 μM

5.70

-7.71

433

2.97

JG-03-12

2.6 μM

5.58

-7.61

221

4.88

>50 μMf

1.1μM

5.95

-8.12

455

3.34

7.1 μM

1.4 μM

5.85

-7.98

351

3.59

7.5 μM

JG-03-13

5 μM

5.30

-7.23

163

1.48

JG-05-1A

1.9 μM

5.72

-7.80

508

5.62

>50 μMf

JG-05-2A

4.2 μM

5.37

-7.33

149

6.58

>50 μM

JG-05-7

10 μM

5.00

-6.82

152

2.43

>50 μM

JG-05-2B

13 μM

4.89

-6.66

136

2.90

>50 μM

10 μM

5.00

-6.82
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4.63

>50 μM

10 μM

5.00

-6.82

27

6.66

>50 μM

>10 μM

4.00

-5.45

-241

3.69

>50 μM

>20 μM

3.70

-5.04

296

9.02

>50 μM

2 μM

5.70

-7.77

563

3.24

N/D

2 μM

5.70

-7.77

455

3.70

N/D

A

JG-05-1B

JG-05-4
B

JG-05-6

JG-03-9

C

JG-03-4
d

JG-03-8

JG-05-3Ad
e

Colchicine

DAMA-colchicinee

N/A

a

>50 μMf
>50 μMf

>50 μMf

Antiproliferative activity against human MDA-MB-435 cells using the SRB assay.
Microtubule depolymerizing activity for microtubule loss.
c
From reference 110.
d
pIC50 and ΔGbinding calculated for 10×IC50.
e
Reported colchicine IC50 data was an average of values reported previously in the literature, references
110. For calculation purposes DAMA-colchicine was assumed to have same binding as colchicine.
f
Mechanism of cytotoxicity appears to be unrelated to microtubule disrupting activity.
N/A – not applicable; N/D – not determined.
b
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Results of a second assay, microtubule depolymerizing activity EC50s for microtubule
loss that serves as a partial check on mechanism of action, are also reported in Table 2.

2.3.2 The Colchicine Binding Site
Binding models for each pyrrole analogue were investigated to delineate steric,
electrostatic and hydropathic features of the colchicine binding site. Because we have
focused on a series of eighteen compounds with IC50s ranging over more than three
orders of magnitude (see Table 2), we performed detailed docking studies with
GOLD69,139 followed by free energy scoring using the HINT protocol91,102 to assess the
binding modes. Without added constraints GOLD was found to reliably re-dock the
crystallographic DAMA-colchicine ligand (RMSD = 0.76 Å) that was then used as the
reference for all other docking experiments. The HINT score for co-crystallized DAMAcolchicine was 139; in the re-docked pose this score was 455. However, docking of the
pyrrole analogues with GOLD produced a mixture of orientations that could not be
rationalized with the GOLD docking score. Thus, as we have described in an earlier
report96, docked poses were re-scored with HINT and we chose the highest HINT-scored
pose for further analysis (see Table 2).

Docking poses created using a variety of

constraints (see Methods) did not yield higher scoring models and were less interpretable
than the “freely” bound models we are using. These docked models of substituted
pyrroles fit within the pharmacophoric model proposed by Nguyen et al.131, and for the
structural features in common between the substituted pyrroles and in the Nguyen et. al.
study, the docking models are in generally good agreement. Key is that the hydrophobic
methoxy substituted ring of the pyrrole analogues sits at the hydrophobic center where
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the TMP moiety of colchicine is found. Note that, although the pyrrole compounds have
quite similar structures and are generally positioned in the binding pocket with essentially
the same mode, the HINT scores are very sensitive and slight positional differences are
detectable in the scores. This sensitivity combined with the number of compounds in the
data set allowed us to analyze the site in considerable detail.

The focus of these computational investigations was on structural aspects of the
interactions. The colchicine binding site lies at the interface between the α and β subunits
of tubulin, mostly in the β subunit lined by helices 7 and 8 (see Figure 5). The funnelshaped binding cavity has a volume of about 600 Å3. Residues Tyr202β, Val238β,
Thr239β, Cys241β, Leu242β, Leu248β, Leu252β, Leu255β, Ile378β, and Val318β form
the narrow funnel end-like part and confer a strong hydrophobic character to this part of
the cavity.

At the wider portion, the cavity is surrounded by Ala250β, Asp251β,

Lys254β, Asn258β, Met259β, Ala316β, Ala317β, Thr353β and Ala354β making it
moderately polar/moderately hydrophobic.

The open mouth end is surrounded by

Asn101α, Thr179α, Ala180α, Val181α and Thr314β, Asn349β, Asn350β, Lys352β. The
crystal structure for the complex indicates that DAMA-colchicine (and presumably
colchicine) is positioned in the pocket such that its tri-methoxyphenyl (TMP) moiety sits
snugly in the narrow hydrophobic pocket. Colchicine also forms hydrogen bonds with
the backbone amides of Ala180α and Val181α.
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Figure 5: Colchicine binding site at the interface between the α and β subunits of tubulin.
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2.3.3 Structure-Activity Binding Relationships
The pyrrole analogues were clustered into three activity sets in order to study them in
detail (see Table 2). The first set (A) was comprised of substituted pyrroles that showed
antiproliferative activity with sub-µM IC50s. The second set (B) consisted of ligands with
IC50 values ranging from 1 μM to 5 μM. The remaining ligands, with IC50 values above 5
μM, comprised the third set (C). The analogs from subset A have noticeable similarity in
their structures and are relatively simpler molecules than those in sets B and C. For all of
these (set A) compounds the pyrrole ring is substituted by bromines at the 3 and 5
positions and an ethyl ester group at position 2. The differences among this group are
substitutions to the phenyl ring at the 4 position of pyrrole. In these, the more potent
compounds, most substituents to the phenyl ring, i.e., Cl, Br and methoxy, serve to make
this portion of the ligand hydrophobic. Figure 6A illustrates the final docked orientations
of the high-affinity pyrroles in the colchicine site of tubulin. The hydrophobic substituted
phenyl ring fits snugly in the hydrophobic (narrow funnel) region of the binding pocket.
The docked model for JG-03-14 is qualitatively similar to one reported earlier108.

HINT hydropathic analysis reveals more detail concerning the forces orienting these
ligands in the binding site. First, hydrophobic interactions are the dominating force
contributing towards the stability of the complexes, with additional hydrogen-bonding
interactions anchoring the ligands in the cavity. As listed in Table 2, the most potentbinding ligand has the highest HINT score (vide infra), i.e., JG-03-14 interacts with the
binding site residues forming the most stable complex. The methoxy-substituted phenyls
are positioned deep in the hydrophobic cavity surrounded by Cys241β, Leu242β,
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Figure 6: Pyrrole analogues docked at colchicine binding site. (A) Substituted pyrroles
with activity in sub-μM IC50. (B) Ligands with IC50 ranging from 1 μM to 5 μM. (C)
Ligands with IC50 value above 5 μM.

a

b

c
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Leu248β, Ala250β, Leu255β, Ala354β and Ile378β, all of which contribute to favorable
hydrophobic-hydrophobic binding. Figure 7 illustrates these interactions in a HINT map,
where the relative sizes of the displayed contours represent the strength, and the colors
represent the character, of the interactions between JG-03-14 and the tubulin colchicine
binding site. The phenyl ring of JG-03-14 fits in a hydrophobic glove formed by the
Leu248 and Leu255. Favorable polar interaction with Asn101, Cys241 and Asn258 also
contribute in binding. The ethyl ester tail of the ligand faces towards the polar opening
and is stabilized with a strong hydrogen-bond to the amide oxygen of Asp258β with a
length of 2.41 Å. Another set of strong hydrogen-bonds are formed between the amine of
Asn101α and the carbonyl oxygen (1.48 Å) and alcoholic oxygen (2.72 Å) of the ligand’s
ethyl ester substituent. This latter feature, anchoring of the flexible ethyl ester tail, is
somewhat different in our models as compared to those of Nguyen et al131, probably due
to the lack of steric constraints at the open polar end of the cavity.

On analyzing subset B, docked ligands in the low μM range, it can be seen that these
ligands are somewhat similar to the subset A ligands, but with slightly bulkier groups
overall as in JG-03-12, JG-05-6 and JG-05-1A, more highly substituted at the pyrrole
ring as in JG-03-12, and/or with less hydrophobic substituents as in JG-03-13, JG-05-4,
and JG-05-8.

For example, in JG-03-13 the single chlorine substitution is less

hydrophobic than the two bromines of JG-03-14 and having only one methoxy also
reduces this compound’s hydrophobicity. In the case of JG-05-8 only a single methyl
group substitutes the phenyl ring at the para position.
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Figure 7: HINT interaction maps for JG-03-14 (ball and stick rendering) at colchicine
binding site. Blue contours represent regions of favorable polar interactions, e.g.,
hydrogen bonds, red contours represent unfavorable polar interactions and green contours
represent favorable hydrophobic interactions.
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JG-03-12 and JG-05-1A have bulkier substitutions at the 5 position of the pyrrole, likely
leading to their higher (less potent) IC50 values. The docked models (Figure 6B) and
detailed HINT analysis confirm this SAR by showing a relatively poor fit in the active
site for the bulkier ligands, and poorer hydrophobic HINT scores for the less optimallysubstituted ligands. A single exception, the napthyl-substituted JG-05-6 produces a high
HINT score inconsistent with its relatively low potency, but this may be due to this
compound being too hydrophobic (Table 2) for solubility or transport to the site (vide
infra).

Lastly, many of the subset C (inactive) ligands (Figure 6C) do not fit well in the site,
while others are inappropriately decorated to make the required contacts with the site
residues. Many of them have one or more bulkier substituents on the pyrrole ring, and
only fit in the binding pocket with their side chains protruding out of the pocket.

2.3.4 Predictive Models for Ligand Binding
Figure 8 presents the correlation between the experimental binding (ΔGbinding as
calculated from IC50, see Methods) in kcal mol-1 and HINT scores for the eighteen
synthetic pyrroles in this study. The IC50s, antiproliferative activities of the compounds,
are being taken in this work as approximations of binding affinity, with the implicit
assumption that the antiproliferative activity is wholly due to tubulin binding. The
consequences of this assumption will be discussed below.
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Figure 8: Dependence of the experimental ∆G on HINT score units for Tubulin-pyrrole
complexes. The solid black line represents the regression for ∆G vs. HINT score for all
protein-ligand complexes. The red line represents the regression for ∆G vs. HINT score
excluding the circled outlier (JG-05-3A).
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The trend represented by the plot of Figure 8 indicates that higher scoring complexes are
generally among those with more favorable free energies of binding, while lower scoring
complexes are generally those with unfavorable binding. The correlation equation:

ΔG = –0.0039 HTOTAL – 6.35,

(8)

has an r2 = 0.5818 and a standard error of ± 0.52 kcal mol-1. A better correlation is
observed after omitting the outlier JG-05-3A from the correlation.

Although this

compound shows a high HINT score suggesting optimal intermolecular interactions
within the tubulin colchicine site, it has a very high logPo/w value of 9.02 (Table 2)
suggesting that this compound would likely not be transported to the binding site and
may even be insoluble. The scoring function does not take into account cell permeability
and completely ignores whether or not the compound could in vivo or in vitro be
accessible to the binding site. Thus, the unfavorable physiochemical properties of JG-053A, and not statistical evaluation, warrant excluding it from the model and justify treating
it as an outlier. Ignoring this outlier gives an r2 = 0.76 and a standard error of ± 0.41 kcal
mol-1, with a very similar correlation equation:

ΔG = –0.0039 HTOTAL – 6.51,

(9)

We believe that this model is predictive such that we can identify the active (subset A)
ligands from the inactive (subset C) ligands with reasonable confidence and that further
refinement of the model with additional data will improve its usefulness. However, it
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must be noted that the EC50 for tubulin depolymerization data (Table 2) suggest that
several of the compounds (two in set A) that dock in the colchicine binding site with high
HINT scores do not appear to cause perturbations of cellular microtubules, i.e., their
interactions within the colchicine binding site may not be the mechanism of cytotoxicity.
Thus, while we cannot state that all antiproliferative activity is due to tubulin binding in
the pyrrole compounds, there is enough experimental information for several of the more
active compounds, and a compelling case for JG-03-14, to believe that designing ligands
to bind with optimimum interactions in the tubulin colchicine binding site will produce
compounds that will likely disrupt cellular microtubules and cause antimitotic actions.

2.4 Summary
The present communication demonstrates that the state-of-the-art molecular modeling
calculations along with HINT interaction calculations are able to complement
experimental studies of binding in many aspects, including accurate representation of the
structure of the complex and the binding mode of putative drugs. The structural analysis
of the binding pocket has identified important intermolecular contacts that mediate
binding. The complex with JG-03-14 has the highest binding score corroborating the
experimental data. In conclusion, the present series of pyrrole analogues have yielded
representative compounds that are potent tubulin polymerization inhibitors and others
that bind with less efficacy, but that still provide useful information for designing
compounds with improved performance and selectivity.
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CHAPTER 3
Hydropathic Analysis and Biological Evaluation of Stilbene
Derivatives as Colchicine Site Microtubule Inhibitors with AntiLeukemic Activity.

3.0 Abstract
The crucial role of the microtubule in the cell division has identified tubulin as a target
for the development of therapeutics for cancer; in particular tubulin is a target for
antineoplastic agents that act by interfering with the dynamic stability of microtubules. A
molecular modeling study was carried out to accurately represent the complex structure
and the binding mode of a new class of stilbene-based tubulin inhibitors that bind at the
αβ-tubulin colchicine site. Computational docking along with HINT score analysis fitted
these inhibitors into the colchicine site and revealed detailed structure-activity
information useful for inhibitor design. Quantitative analysis of the results was in good
agreement with the in vitro antiproliferative activity of these derivatives (ranging from 3
nM to 100 μM) such that calculated and measured free energies of binding correlate with
an r2 of 0.89 (standard error ± 0.85 kcal mol-1). This correlation suggests that the activity
of unknown compounds may be predicted.
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3.1 Introduction
Stilbene-based compounds are largely present in nature and have become of particular
interest to chemists and biologists because of their wide range of biological
activities141,142. Stilbene itself does not occur in nature, but hydroxylated stilbenes have
been found in many medicinal plants. The hydroxylated stilbene trans-resveratrol (trans3,40,5-trihydroxystilbene, Figure 9) is a phytoalexin present in grapes and plays a role in
the prevention of coronary artery disease associated with red wine consumption141,143-145.
Resveratrol has also antioxidant and anti-inflammatory properties and could be a
potential chemopreventive and therapeutic agent in cancer146,147. In vitro inhibition of cell
proliferation148 and in vivo anti-neovascularization by resveratrol have been
demonstrated149. On the other hand, the cis-stilbene motif represents a key structural
feature of a broad class of natural and synthetic compounds endowed with an
exceptionally strong tubulin polymerization inhibitor activity interfering mainly with
microtubule formation at the tubulin colchicine binding site. In this context, the natural
cis-stilbene combretastatin A-4 (CA-4) (Figure 9), an antimitotic agent isolated from the
bark of the South African tree Combretum caffrum, and its 30-amino derivative (AC7739) possess potent and interesting antitumor activity150,151.

Combretastatins have been demonstrated to bind at the colchicine binding site and
destabilize microtubule assembly and prevent spindle formation in mitotic cells152. The
relatively simple structure and high affinity of combretastatins for the colchicine binding
site has led to the synthesis and subsequent evaluation of a large number of
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Figure 9. Natural and synthetic stilbenes
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analogues; novel compounds derived from this core continue to hold interest as potential
therapeutics152-154. Stilbene and its analogues (Figure 9 a, b) are structurally similar to
combretastatin and are also able to bind to microtubules, suppress microtubule dynamics,
and arrest the cell cycle at a G2/M phase that is associated with induction of
apoptosis155,156.

Their mechanism of action is related to tubulin-binding properties that result in rapid
tumor endothelial cell damage, neovascular shutdown and subsequent hemorrhagic
necrosis157. Our collaborative group has recently synthesized a series of derivatives
structurally related to both resveratrol and CA-4, in cis and trans orientations.
Modifications were made by placing OH, NH2, or OCH3 groups at positions 30 and 40
and OCH3 at positions 3,5. The IC50 for each of each stilbene was tested in HL60 cells.
Several active stilbenes were identified and, among them, cis-3,40,5-trimethoxy-30aminostilbene (5C) and cis-3,40,5-trimethoxy-30-hydroxystilbene (6C) were found to
induce HL60 apoptosis at nanomolar concentrations (IC50 = 30 nM)158. Examination of
the structures of stilbenes 5C and 6C reveals similarity to colchicine, combretastatin
CA4158, ZD6126, and AVE-8062.

The new stilbenes interfere with microtubule formation at the tubulin colchicine binding
site (Figure 10), in a similar manner as CA-4 and AC-7739, inducing apoptosis in HL60
leukemia cells, but not in normal c-kit-positive hematopoietic progenitor cells at similar
concentrations156. These two stilbenes have a similar cytotoxic effect in HL60 cells
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Figure 10. The Tubulin-colchicine:RB3-SLD complex, The complex includes
alternating tubulin αβ heterodimers, with the colchicine binding site at the intradimer
interface, the taxol binding site on the β subunit and the vinblastine binding site at the
interdimer interface of the αβ subunit.
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expressing multiple-drug resistant gene158, which is responsible for chemotherapeutic
resistance to anthracycline in leukemia. In addition to the effect in leukemia cells,
stilbene 5C is also highly potent against various solid tumor cells and blocks cell cycle
progression in G2-M phase158. Stilbene 5C is tolerated in mice up to 100 mg/kg by
intraperitoneal injection without major organ toxicity. In particular, there was no bone
marrow toxicity, and the ability of bone marrow engraftment was not affected by stilbene
5C treatment156. Similar to other colchicine site tubulin inhibitors, stilbene 5C selectively
suppresses tumor vascular perfusion without damaging normal vascular perfusion based
on a DCE-MRI study159. Most importantly, mice treated with five daily injections of 5C
at 25 mg/kg/day did not show any compromise in heart function, indicating that it could
be a colchicine site inhibitor with negligible cardiotoxicity159.

As the synthesis of stilbene analogues is relatively facile, our goal for this study was to
create a quantitative structure-activity model of these compounds that would guide the
synthesis of new, potentially more efficacious stilbene derivatives. Thus, we report here
on the structural requirements for interaction between stilbene analogs and tubulin with
computational docking and hydropathic scoring of multiple stilbene analogs into the
colchicine-binding site of tubulin.

3.2 Materials and Methods
3.2.1 Synthesis
Synthesis of stilbenes 5c, 6c and its analogs (Figure 11) was performed as described by
Roberti et al.158 who provided all samples for bioactivity analysis.
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Figure 11: Stilbene analogs
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3.2.2 Antiproliferative Activity of Stilbenes against Human Tumor Cell
Lines
The antiproliferative activity of stilbene derivatives was determined by Alamar BlueTM
staining. The bioassays were carried out in the lab of Dr. Ray Lee at Massey Cancer
Center, VCU. In brief, cells were grown in 96-well plates and treated with 0, 0.01, 0.03,
0.1, 0.3, 1.0, and 3.0 μM of the stilbene for 48 hours before being harvested for Alamar
blueTM staining. In this staining, 1/10 volume of Alamar Blue™ solution was added to
each well and optical density (OD) at 570 and 600 nm was determined by a microplate
reader.

The percentage of growth inhibition was calculated according to the

manufacturer’s formula as follows: [(117216 x A570) –(80586 x A600)]/[(117216 x Ao570)(80586 x Ao600)] x 100. In this formula, A570 is the absorbance of the treated samples at
570 nm; A600 is the absorbance of the treated samples at 600 nm; Ao570 is the absorbance
of the untreated samples at 570 nm; and Ao600 is the absorbance of the untreated samples
at 600 nm. The two constants, 117216 and 80586, are the extinction coefficients of
Alamar Blue™ at 570 and 600 nm respectively. Each concentration was repeated in
triplicates.

3.2.3 Model Building
The X-ray crystal structure (3.58 Å) of αβ-tubulin complexed with DAMA-colchicine132
(PDB code: 1SA0) was used in this study. The stathmin-like domain and the C and D
subunits were removed from the model. After hydrogen atoms were added to the model,
their positions were optimized to an energy gradient of 0.005 kcal-Å/mol with the Tripos
force field (in Sybyl 7.3) while keeping heavy atom positions fixed. The models for stilbene
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analogues were constructed using the Sybyl 7.3 (www.tripos.com) suite and optimized
similarly78.

3.2.4 Docking
Computational docking was carried out using the genetic algorithm-based ligand docking
program GOLD 3.069. GOLD explores ligand conformations fairly exhaustively and also
provides limited flexibility to protein side chains with hydroxyl groups by reorienting the
hydrogen bond donor and acceptor groups. The active site was defined by using
colchicine as the reference molecule in the protein active site creating an approximate
radius of 10 Å around the reference molecule using the GOLD cavity detection
algorithm. Because of the relatively poor resolution of the X-ray crystal structure and
following the approach of Nguyen et al.131, GOLD docking was carried out with template
similarity constraints. This constraint biases the conformation of docked ligands towards
a given solution. The trimethoxyphenyl fragment of colchicine was used as the template
for biasing the pose of all ligands. In this study we performed 100 GOLD genetic
algorithm runs, as opposed to the default of 10 and early termination of ligand docking
was switched off. All other parameters were as the defaults. To evaluate and validate
GOLD performance the co-crystallized ligand DAMA-colchicine132 was extracted and
docked. GOLD accurately reproduced the experimentally observed binding mode of
DAMA-colchicine in αβ-tubulin. Combretastatin was docked first and the resulting
model was scored and optimized. The remaining stilbene analogs were docked and
optimized using combretastatin as a reference within 0.5 Å RMSD by using the same
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parameters. Docked ligands were scored using the HINT force field scoring function and
iteratively optimized for maximal interaction.

Dockings with different/optional constraints such as enforced hydrogen bonds,
hydrophobic regions and scaffold match were also explored.

For hydrogen bond

constraints, docking was biased so that the ligands make hydrogen bonds with Asn258,
Ser178, Asn101, and the backbone amides of Ala180 and Val181. For region
hydrophobic constraints the ligand positions were constrained by defining a hydrophobic
sphere where the tri-methoxy phenyl moiety of colchicine was positioned. Then specific
ligand atoms to be docked in the hydrophobic region of the active site were defined.
Alternatively, scaffold match constraints were used to place the ligand at a specific
position within the active site. Generally, however, because the binding site is rather
featureless, constraint or template-free docking was not successful.

3.2.5 Hydropathic Scoring
The HINT (Hydropathic INTeractions) scoring function91 (version 3.11S β) was used to
investigate the structural aspects of the interactions by analyzing and ranking the GOLD
docking solutions. For selection of the optimum docked conformation and to further
differentiate the relative binding efficacy of the stilbene ligands, interaction scores were
calculated for each pose found by docking. The protein and ligands were partitioned as
distinct molecules. “Essential” hydrogen atoms, i.e., only those attached to polar atoms
(N, O, S, P) were explicitly considered in the model and assigned HINT constants. The
inferred solvent model, where each residue is partitioned based on its hydrogen count,
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was applied. The solvent accessible surface area for the amide nitrogens of the protein
backbone were corrected with the “+20” option. Finally, HINT scores were plotted
against experimental binding free energy.

3.3 Results and Discussion
3.3.1 Antiproliferative Activity of Stilbene Analogues
The biological activity of all compounds was tested in UCI101 ovarian cancer cells and
qualitatively similar trends were observed in MDA-MB231 breast cancer cells160.
Compounds could be separated into three groups according to their potency. Group A
contains the most potent compounds, including combretastatin, stilbene 5C, GG251,
colchicine, DAMA-colchicine, VT23 and stilbene 6C with IC50 less than 100 nM. Group
B contains GG240, GG247, GG245, GG249, which has IC50 in the intermediate range
between 0.3 and 1.0 μM. Group C is not active with IC50 above 5 μM (see Table 3).

3.3.2 The Colchicine Binding Site
A number of groups have performed modeling studies on the colchicine binding site
because it is recognized as a potential target for anticancer drug development131.
However, the low resolution of the available crystal structures for tubulin have made it
difficult to fully delineate the essential structural and functional features involved in
tubulin inhibition. In a low resolution crystal structure model our knowledge of the
correct orientation of sidechains is limited by ambiguities in position and orientation
because the experimental electron density envelopes are generally featureless. The crystal
structure of tubulin protein used in this study has a fairly poor resolution of 3.58 Å, which
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Table 3: Experimental IC50 and docking results for Stilbene and Campione derivatives.

Compound

Activity
Set

IC50

a

pIC50
b

ΔGbinding
(kcal
-1
mol )

HINT
score

HINT
LogP

3.3 ± 0.4 nM

8.53

-11.62

1015

4.43

Stilbene 5C

32 ± 4 nM

7.53

-10.26

860

4.05

GG251

28 ± 3 nM

7.53

-10.26

861

4.73

30 ± 2 nM

7.53

-10.26

841

3.24

29 ± 2 nM

7.53

-10.26

810

3.70

Combretastatin

Colchicine

A

DAMA-colchicine
Stilbene 6C

52 ± 7 nM

7.30

-9.96

673

3.94

VT23

65 ± 8 nM

7.22

-9.85

446

3.17

GG240

0.32 ± 0.02 μM

6.52

-8.89

579

2.85

GG247

0.30 ± 0.04 μM

6.52

-8.89

563

3.99

B

1.0 ± 0.08 μM

6.00

-8.18

285

3.44

GG249

1.1 ± 0.07 μM

6.00

-8.18

278

3.10

CTR104

5.2 ± 0.9 μM

5.30

-7.23

252

5.60

CTR105

10 ± 0.9 μM

5.00

-6.82

-202

2.44

105 ± 6 μM

4.00

-5.45

49

5.44

GG245

CTR103

C

CTR106

110 ± 12μM

4.00

-5.45

-446

5.37

VT54

107 ± 14μM

4.00

-5.45

-313

2.98

a

Antiproliferative activity against UCI-101 ovarian cancer cell line using the Alamar
Blue assay.
-pIC50 and ΔGbinding calculated for 10×IC50.
-Colchicine IC50 data was recorded against UCI-101 ovarian cancer cell line. For
calculation purposes DAMA-colchicine was assumed to have same binding as
Colchicine.
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somewhat undermines our ability to structure-based design highly selective ligands132. In
earlier studies with the colchicine binding site we carried out computational docking
studies along with hydropathic interaction analysis on a family of substituted pyrroles and
were able to represent the complex structure and the binding modes of the pyrrole class
of inhibitors (see chapter 2)100.

Binding modes for each stilbene analogue were investigated to understand the steric,
electrostatic, and hydropathic features of the colchicine binding site. A molecular
modeling study of docking these ligands into the colchicine site of αβ-tubulin was carried
out in order to accurately represent the complex structure. The colchicine binding site is
positioned at the interface between the α and β subunits of the tubulin protein, with the
major part of it buried in the β subunit and lined by helices 7 and 8. The cavity, which is
funnel shaped, has a volume of about 600 Å and opens up towards the α subunit of the
interface surrounded by residues Asn101α, Thr179α, Ala180α, Val181α and Thr314β,
Asn349β, Asn350β, Lys352β. The other, β subunit, end of the cavity is surrounded by
residues Tyr202β, Val238β, Thr239β, Cys241β, Leu242β, Leu248β, Leu252β, Leu255β,
Ile378β, and Val318β and forms the narrow funnel end-like part of the cavity. The
predominance of hydrophobic residues confer a strong hydrophobic character to this part
of the cavity. At the wider portion, the cavity is surrounded by Ala250β, Asp251β,
Lys254β, Asn258β, Met259β, Ala316β, Ala317β, Thr353β and Ala354β making it
moderately

polar/moderately

hydrophobic.

DAMA-colchicine

(and

presumably

colchicine) is snugly positioned in the crystal structure of the complex. The
trimethoxyphenyl (TMP) moiety of colchicine is positioned in the pocket such that its sits
snugly in the narrow hydrophobic region of the pocket with one of its methoxy oxygens
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involved in hydrogen bonding with the thiol of Cys241β. Colchicine also forms hydrogen
bonds with the backbone amides of Ala180α and Val181α.

The structural complex as reported in the X-ray structure was refined through ligand
functional group and protein sidechain optimization, as incorporated in the HINT
program. Iteratively, colchicine was translated and rotated and optimized for interactions.
Taking colchicine as the template, combretastatin was computationally docked and
scored. Similar to above, the combretastatin-tubulin complex was optimized. Next, the
stilbene analogs were docked, this time taking combretastatin as the template, followed
by HINT functional group and protein sidechain optimization. The docked models of the
stilbene analogs fit within the pharmacophore model proposed by Nguyen et al.131 and
are similar to the models we reported earlier in chapter 2 for the pyrrole derivatives
bound to αβ-tubulin100. These studies, coupled with HINT interaction analyses, are able
to describe the complex structure and the binding modes of stilbene inhibitors. Note that
HINT scores are very sensitive and slight positional differences are detectable in the
scores. Qualitative analyses of the results showed general agreement with the
experimental in vitro antiproliferative activity for these derivatives.

3.3.3 Structure-Activity Binding Relationships
Structural analysis of the binding pocket identified important intermolecular interactions
that mediate binding. The stilbene analogues were clustered into three activity sets in
order to study them in detail (see Table 3). The first (A) was comprised of compounds
that showed activity from 3 nM to 60 nM IC50. The second (B) consisted of ligands with
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IC50 values ranging from 0.3 μM to 1 μM. The remaining ligands, with IC50 values of 5
μM and above, comprised the third set (C).

HINT hydropathic analysis reveals

significant detail concerning the forces orienting these ligands in the binding site. First,
hydrophobic interactions are the dominating force contributing towards the stability of
the complexes, with additional hydrogen-bonding interactions anchoring the ligands in
the cavity. The trimethoxyphenyl (TMP) moieties of colchicine and combretastatin are
positioned within the narrow hydrophobic region of the cavity while the carbonyl oxygen
on the unsaturated seven-member ring of colchicine and the hydroxyl group on
combretastatin B ring are anchored through strong hydrogen bonding interactions with
Asn258β and the Ala180α and Val181α backbone amides.

First, in examining the docked models for activity subset A (see Figure 12A), it is
interesting to note that, although the stilbene compounds and combretastatin are quite
dissimilar structurally to colchicine (excepting the TMP moiety), they are generally
positioned in the binding pocket with essentially the same mode. In the case of stilbene
5C and GG251 the hydrophobic substituted phenyl ring fits snugly in the hydrophobic
(narrow funnel) region of the binding pocket that superimposes on the TMP moiety of
colchicine. In fact, stilbene 5C and GG251 have a very similar binding mode to that of
combretastatin, the major contribution towards binding coming from hydrophobic
interactions. The methoxy substituted phenyls are positioned deep in the hydrophobic
cavity surrounded by Cys241β, Leu242β, Leu248β, Ala250β, Leu255β, Ala354β and
Ile378β, all of which contribute to favorable hydrophobic-hydrophobic binding. The
phenyl ring of Stilbene5C and GG251 fits in a hydrophobic glove formed by the Leu248β
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and Leu255β. Favorable polar interaction with Asn101α, Cys241β and Asn258β also
contribute to the tight binding. The NH2 group on the B ring of Stilbene5C faces towards
the polar opening and is stabilized with a strong hydrogen-bond to the amide oxygen of
Asn258β with a length of 2.55 Å. Another set of strong hydrogen bonds is formed
between the amide backbone of Val181α and the amine on the B ring of Stilbene5C with
a hydrogen bond distance of 3.384 Å. However, in the case of GG251 the hydrogen
bonding interaction is not observed with the Asn258β and Val181α amide backbone,
instead the complex is predominantly stabilized through hydrophobic interactions.
Similar interactions are observed with stilbene 6C and VT23 with some subtle
differences.
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Figure 12. Stilbene analogs docked at the colchicine binding site on αβ-tubulin. (a)
Substituted stilbenes with activity in sub-μM IC50. (b) Compounds with IC50 ranging
from 0.3 μM to 1.0 μM. (c) Compounds with IC50 values above 5 μM.
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In the case of stilbene 6C, although the hydroxyl group is retained on the B ring as in
combretastatin, the removal of methoxy group from the position 4 of TMP moiety results
in loss of activity. However, this loss is offset by introducing the NH2 group on ring B in
stilbene 5C, thus accounting for the slight differences in their activity. In the case of
VT23 the extension of methoxy chain on TMP moiety results in further loss of activity
probably due to geometric constraints enforced by the narrow hydrophobic region of the
cavity.

On analyzing subset B (compounds GG240, GG247, GG245, and GG249), docked
ligands in the low μM range, it can be seen that these ligands are relatively similar to the
subset A ligands. In this set of compounds substitution on ring B, in the cases of GG240,
GG247 and GG249 the indole-carrying ring and in GG245 the amine and methoxy
carrying ring, is varied. These substitutions result in a 10-fold decrease in the activity in
compounds GG240 and GG247 where the N-methyl substitution is removed from the
indole ring of GG251. Flipping the ring, as in the 6- and 5- substituted indole ring of
GG240 and GG247, does not have any significant affect on activity. Activity is further
decreased if the indole ring is replaced by a benzimidazole ring as in compound GG249
and a similar loss in activity is noted in GG245 where the methoxy groups of the stilbene
5C methoxy phenyl moiety is replaced by a methyl group and a hydroxyl group,
confirming the importance of the methoxy phenyl moiety on ring A in binding. The
benzofuran and benzothiophene analogs in the CTR series of compounds (subset C) are
similar to 2-aroylindoles, where the 2-aroylindole ring is replaced by benzofuran and
benzothiophene. Our docked complexes with the CTR series of compounds agree with
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the Nguyen et al. pharmacophore model131, but the rings are inappropriately substituted
to make the required contacts with the binding site residues – leading to poor activity of
these compounds. Figure 13 represents the putative binding mode of Stilbene 5c, the
most potent compound of the series.

3.3.4 Predictive Models for Ligand Binding
Figure 14 presents the correlation between the experimental binding (ΔGbinding as
calculated from IC50) in kcal mol-1 and HINT scores for the synthetic stilbene analogs in
this study. The trend represented by this plot indicates that higher scoring complexes are
generally among those with more favorable free energies of binding, while lower scoring
complexes are generally those with unfavorable binding. The correlation equation:

ΔG = –0.0041 HTOTAL – 6.877,

(10)

has an r2 = 0.898 and a standard error of ± 0.85 kcal mol-1.

The IC50s, antiproliferative activities of the compounds, are being taken in this work as
approximations of binding affinity. The scoring function does not take into account cell
permeability and completely ignores whether or not the compound could in vivo or in
vitro be accessible to the binding site.
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Figure 13: Representation of interactions of stilbene 5C in the colchicine active site of
the tubulin protein.
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Figure 14. Correlation plot between free energy of binding, ∆G vs. HINT score. The line
represents the regression for ∆G vs. HINT score for all protein-ligand complexes in this
study.
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However, the similar structures of these compounds and the fairly narrow range of LogPs
suggest that these properties would be similar, if not the same, for all of these
compounds, and thus can probably be ignored while comparing the compounds within
the series.

We believe that the model of Figure 14 is predictive such that it can

distinguish the active (subset A) ligands from the inactive (subset B) ligands with
reasonable confidence. Refinement of the model with additional data will further improve
the understanding of binding process and predictive ability of the model.

3.4 Summary
The aim of this study was to accurately represent the complex structures and the binding
mode of a new class of stilbene-based tubulin inhibitors. Both qualitative and quantitative
analysis of the results suggested that the model was in general agreement with the in vitro
antiproliferative activity observed experimentally for these compounds. A good
correlation between the modeled interaction energies and estimated free energies of
binding calculated from IC50 suggest that our model is able to represent the complex
structures and the binding modes of inhibitors and under some circumstances be
predictive with respect to new members of the stilbene series. We believe that we can
identify active ligands from inactive ligands with reasonable confidence; our analysis has
provided a rationale for selecting substituents that will yield more tightly binding
analogues.
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CHAPTER 4
A Novel and Efficient Tool for Identifying and Characterizing
Protein Cavities and Binding Sites.

4.0 Abstract
Systematic investigation of a protein and its binding site characteristics are crucial for
designing small molecules that modulate protein functions. However, fundamental
uncertainties in binding site interactions and insufficient knowledge of the properties of
even well-defined binding pockets have often made it difficult to design effective drugs
with optimal activity. Herein, we report the development and implementation of a novel
cavity detection algorithm that utilizes HINT toolkit functions that we are naming VICE
(Vectorial Identification of Cavity Extents). This algorithm, which is based on geometric
criteria applied to simple integer grid maps to delineate binding sites, is very efficient. In
testing, we carried out a systematic investigation on a diverse set of proteins for locating
and characterizing the indentations, cavities, pockets, grooves, channels and surface
regions on proteins, protein-protein and protein-polynucleotide complexes.

An

interactive front-end provides a quick and simple procedure for identifying, displaying
and manipulating cavities in a known protein structure. Information describing the cavity
including its volume and surface area metrics, and lists of atoms, residues and/or chains
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lining the binding pocket can be easily obtained and analyzed. For example, the relative
cross-sectional surface area (to total surface area) of cavity openings in well-enclosed
cavities is 0.06 ± 0.04 and in surface clefts or crevices is 0.25 ± 0.09.

4.1 Introduction
Modulation of the dynamics of a target protein binding site to elicit a pharmacological
response is the major therapeutic approach for the treatment of a plethora of diseases.
This is usually accomplished by developing small molecules that occupy a ligand
recognition site. Drug development is a challenging process, owing to fundamental
uncertainties in structural determination and associated issues such as structural and
physicochemical characterization of the binding pockets, even under relatively static
conditions such as in crystals subjected to x-ray analyses. Reliable, rational and efficient
approaches to identifying and characterizing the binding sites of protein and other
bioactive molecules should be valuable in the design of new drugs161. In recent years
there has been a surge in the number of crystal structures deposited in Protein Data
Bank162. Concomitantly, NMR and X-ray crystallography have played an increasingly
crucial role in drug discovery through structure-based methods and virtual screening of
extensive libraries of compounds. Facilitating this has been the design and development
of many computational tools with a large range of functions. In particular, a number of
programs have been developed to de novo identify the binding pockets in proteins161,163.
Such tools have provided valuable information for better understanding protein binding
site architecture.

However, the accurate identification and quantitation of binding
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pockets is not an entirely straightforward process, and the existing computational tools
have numerous strengths and weaknesses.

Proteins have “pockets” for molecules to bind; however, these pockets may not be
observed from an initial inspection. Protein surfaces are formed by numerous cavities
and protrusions that are interlinked through small narrow channels and are often are
interspersed with numerous holes or voids.

However, amidst all of this surface

irregularity, the complex positioning of residues creates specific microenvironments for
ligand recognition, binding and catalysis. These ligand binding sites vary widely in
shape and size and are often roughly classified according to their position on a protein
and/or shape and described as deep pocket, grooves, indentations, surface concavities,
branched pockets, voids, channels, etc. The size and shape of these protein cavities
dictates the three-dimensional geometry of ligands that will bind within, and guides the
important intermolecular contacts that mediate this binding.

Binding sites that are

formed by several neighboring pockets/cavities and auxiliary pockets near the active site
are often suggested as providing additional ligand binding surface, which adds further to
the complexity. Efficient analysis of the shape and size of protein pockets and cavities
thus becomes important as structural changes due to side-chain rotations and backbone
movements, loop motion and/or ligand-induced conformational changes may
significantly alter the topography of the active site. A thorough structural analysis of the
target binding site is critical to propel a drug discovery project forward. There has been
significant progress in this endeavor in recent years161,163,164.
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4.1.1 Theoretical Approaches for Identifying Binding Sites on Proteins.
Identification and characterization of active sites is key in studying protein structure,
particularly when designing molecules that interfere with function and modulate activity.
There are a number of ways in which binding sites or cavities in proteins can be located
and characterized, e.g., with several existing programs such as VOIDOO

165

, LIGSITE

166

, POCKET 167, POCKET-FINDER 168, CAST 169, PASS 170, APROPOS 171, SURFNET

172

, Q-SITEFINDER

173

and others. These programs can be generally classified into

categories according to the approach they take to identify and delineate the cavity: i)
evolutionary methods (structure/sequence alignments); ii) probe/energy-based methods;
and iii) geometric approaches.

Evolutionary methods use a heuristic approach to predict cavities in unknown proteins
from known protein structures based on family and/or functional criteria. With the
abundance of structural- and sequence-related data for many protein families, this
approach has found increased application in identifying and characterizing protein target
binding sites174,175. Structural similarity and three-dimensional templates are used to
compare and classify putative binding sites in uncharacterized protein structures with
unknown functions, e.g., with similarity searches over functional site databases like
LigBase

176

and INTERPRO

177

that detect functional similarity when homology is

minimal. The approach by Bickel et al. 178 uses statistical methods to identify active sites
by residue identity within and outside functional subfamilies. Programs like ConSurf 179
identify functional regions of proteins by surface mapping of phylogenetic information,
while Rate4Site

180

applies evolutionary determinants in mapping the functional regions
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on a protein surface. These methods are likely to continually evolve with the increasing
availability of structural and sequence data from structural genomics projects.

The idea of in silico mapping of protein surfaces was first conceptualized by Lee &
Richards (1971)
1983)

182

181

based on the idea of an “accessible” surface area. Connolly (1982,

suggested the concept of “solvent excluded surface” and developed the

eponymous algorithm for calculating molecular surfaces with a rolling spherical probe.
Later, Kuntz et al. developed an algorithm that fills all pockets and grooves on the
surface of receptor molecule with a set of balls

183

. While the probe sphere radius is

generally 1.4 Å to approximate a water molecule surveying the solvent accessible surface
of the protein, this sphere radius can be varied to map other representations such as the
van der Waals surface. Kuntz et al. used this approach to define the binding site in the
first implementations of the DOCK automated docking program

33,184

. Another novel

approach of using spherical probes on a regular Cartesian point grid was implemented by
Peter Goodford in GRID
simultaneous searches)

186

.

185

and by Martin Karplus in MCSS (multiple copy

In GRID, a binding region on a protein is mapped by

calculating interaction energies between a (functional) probe group placed at each grid
point and the atoms of the protein. In MCSS, about 1000 to 5000 small functional groups
(probes) are interacted with the protein surface simultaneously and energy minima are
calculated to define favorable interaction sites. The generated functional maps of the
binding site indicate the most favorable regions for placing ligand groups with properties
similar to the probes. A number of cavity detection algorithms based on this approach
have been reported: Voorintholt et al. adopted an approach where grids are used to store
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the distance to the nearest atom 187; a similar approach was taken by Del Carpio et al. 188
in searching for pocket regions in a protein; the POCKET program by Levitt and
Banaszak

167

uses a 3D Cartesian grid and spherical probes to map protein surfaces and

pockets using a modification of the marching cubes algorithm; and the CHANNEL
algorithm

189

uses a sphere of radius R to probe a node space that fills the unit cell of a

crystal lattice.

Some probe/energy-based approaches to detect cavities overlap with geometric
approaches in a way that a probe of a specified volume is only used to exclude van der
Waals overlap as the protein surface is surveyed. The VOIDOO program reported by
Kleywegt and Jones 165 uses atom fattening or a flood fill algorithm on a regular 3D grid
to identify and delineate cavities.

Another such widely used algorithm for cavity

detection is LIGSITE developed by Hendlich, Rippmann and Barnickel

166

.

This

algorithm is similar to POCKET, but circumvents many of its drawbacks: first, grid
points within a protein atom’s van der Waals sphere are discarded; next, the remaining
lattice points are scored according to their degree of burial by scanning grid points along
the three Cartesian axes and the four cubic diagonals; and finally, the area delineating
these grid points is clustered to describe contiguous cavities. Another method totally
relying on geometric criteria is the PASS algorithm developed by Brady and Stouten

170

where the cavities in a protein are filled with a set of spheres.

Cavity detection based on alpha shape theory

190

incorporates a different, purely

algorithmic, approach. The Automatic PROtein Pocket Search (APROPOS) method
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developed by Peters, Fauck and Frömmel

171

is based on purely geometric criteria for

identifying binding sites using atomic coordinates. Atoms are represented as a set of
points in 3D Euclidean space and the envelope or surface is derived by Delaunay
triangulation

191

of these points. The alpha shape algorithm describes these surfaces as

lists of adjacent triangles and, depending on the value of alpha, delineates the cavity
shape. The program CAST developed by Liang and Woodward

169

also applies alpha

shape principles along with discrete flow theory to determine the shape of the binding
pocket as a negative image of cavity derived from Delaunay tetrahedrons

191

. Alpha

shapes and Delaunay triangulations are rich in geometric information from which area
and volumes of inaccessible cavities can also be calculated. Most of these algorithms can
fairly easily identify binding pockets and can be used in combination with other drug
design tools to provide valuable information for structure-based drug design projects.

4.1.2 Vectorial Identification of Cavity Extents (VICE)
The present chapter describe our work in developing computational tools for drug design
192,193

. In this chapter we describe a new computer algorithm called VICE for identifying

and delineating the active site in proteins or other biomacromolecules based on geometric
criteria applied to simple integer grid maps using minimal floating point mathematics.
Our objective in this chapter is to find pockets and shallow binding regions that have the
characteristics of receptor sites, identify the amino acid residues surrounding them, and
calculate descriptive metrics regarding the sites. The algorithm was applied to a diverse
set of over 60 proteins in order to locate, investigate and characterize their various
indentations, cavities, pockets, grooves, channels and surface regions. This is a starting
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point towards comprehensive analysis of protein topography with respect to its function
and an efficient and robust method for finding active sites that would be compatible with
other tools and protocols we have developed based on our HINT empirical force field
model 91,96,102.

4.2 Materials and Methods
The dataset of protein complexes in this study consisted of examples from the literature
having binding pockets of diverse shapes, sizes and types. Table 3 lists the proteins
evaluated by their PDB code and the associated cavity type for which the binding sites
were calculated. All protein structure coordinates, in PDB format, were retrieved from
the RCSB (Brookhaven) Protein Data Bank

162

. Molecular modeling was performed

using the Sybyl 7.3 program suite (www.tripos.com) on Irix and Linux workstations

78

.

The protein structures were prepared for this study by removing all the water molecules,
ions, and any cofactors associated with the structure. Hydrogen atoms were added to the
structures using the “Add Hydrogens” tool within the Sybyl Biopolymer module before
further analysis.

The cavity detection and analysis programs were constructed using subroutines from the
HINT toolkit 103. Several new subroutines were composed for 3D map manipulation and
analysis. Of particular value were an enhanced suite of functions for Boolean maps
(where each grid value can only be zero or one) that forms the basis of the search
algorithm as described in the Results and Discussion section. The algorithm provides
several user-adjustable options to optimize the cavity calculation. With these parameters
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it is possible to change the focus from the entire protein to a small region for a detailed
investigation. For the initial surveys in this study, the grid boxes were defined as the
molecular extents of each biomacromolecule with a grid resolution of 1 Å and margin of
3-5 Å. Most importantly, the cavity definition was set at 0.5, which is the fraction of
vectors reaching a protein “wall” instead of the box edge. The maximum unrestrained
path-length (vector length) was set to 20 Å by default but was increased to 40-60 Å to
explore very large cavities or tunnels and channels.

The minimum closed contour

volume was set to 100 Å2 to eliminate small clusters or irrelevant voids. The shaping
factor was usually set to be 0.50, but was varied from 0.35 to 0.6 to interactively smooth
some pockets that presented small and inaccessible sub-pocket regions. In the figures
shown in this chapter, the surface of the pocket was displayed by contouring the cavity
map at a value of 0.5, i.e., matching the cavity definition.

4.3 Results and Discussion
Protein binding regions provide a microenvironment for substrates, inhibitors, other
proteins or biomacromolecules to interact and modulate the protein’s activity. This
chapter describes a computational tool for locating and investigating the binding regions
of protein from a standard PDB file. This section describes and illustrates the algorithm,
outlines the quantitative cavity metrics that can be derived through this algorithm, and
highlights in some detail several of the more than sixty cases we have used to validate the
methodology for this work. The rather remarkable variation that is observed in shapes
and sizes of binding cavities is evident even from this small number of examples.
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4.3.1 The VICE Algorithm
The VICE (Vectorial Identification of Cavity Extents) algorithm is schematically
illustrated through Figure 15 to 21. After the region of interest, which can be the entire
target protein or portions thereof, is defined, a grid cage with user selectable resolution is
created. While 1 Å resolution is typical, larger or smaller values may be appropriate
depending on computational requirements. The key advantage of this algorithm is that
many of the calculations are performed on integers and on integer (Boolean) grid maps so
that the method is very efficient. In the first step grid points occupied by atoms in the
target molecule are set to zero, while those unoccupied are set to one. These latter points
are potentially in the cavity; each will be examined by the algorithm. The search tools
are sets of vectors whose directions are determined by the grid nodes ( Figure 15). In the
first shell the set of 2D vectors are {(1,0);(1,1);(0,1);(-1,1);(-1,0);(-1,-1);(0,-1);(1,-1)},
while in the second shell set the unique 2D vectors are {(2,1);(1,2);(-1,2);(-2,1);(-2,-1);(1,-2);(1,-2);(2,-1)}. Each vector is projected until it reaches an edge of the grid box
(Figure 16) and the nodes that the vector passes through constitute a path list.
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Figure 15: Vector representations of direction: red = shell 1, green = shell 2, blue = shell 3

Figure 16: Vector (starting in green) continues until reaching grid box edge (red) and all
nodes in path (orange shading) are tested.
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Each vector is classified through analysis of its path list (Figure 17) as having: a clear
path to edge, i.e., it does not pass through an occupied node; a blocked path; or is
“stalled”, i.e., it has neither reached the box edge nor has it passed through an occupied
node. These latter vectors are treated as having clear path; their purpose is to ameliorate
the possibility that a very long vector may inadvertently pass through occupied nodes
belonging to another biomacromolecular subunit or because of a slightly curved pocket
entrance. The stalled vector length is a parameter that may be adjusted depending on the
anticipated dimensions of the cavity. The fraction of vectors classified as blocked is
evaluated for each grid point. Thus, each grid point is classified as “inside” or “outside”
the putative cavity based on a parameter with nominal cutoff value of 0.5 (Figure 18). A
few grid points, mostly at the cavity mouth, are ambiguous (e.g., 0.5 ± 0.05); these are
recalculated with additional shells of vectors and tightening criteria until a final
disposition can be determined.

Two steps are applied to refine the cavity definition. First, narrow channels, i.e., one grid
node in width, and tendrils are eliminated by forcing a requirement that each “inside”
point have a minimum of “inside” neighbors (Figure 19). This can be applied recursively
to “shape” the cavity. Lastly, to eliminate stray irrelevant pockets, each enclosed surface
must have a minimum volume.

While these steps can be performed automatically

without user input, the algorithm is designed to display the intermediate raw maps and
allow interactive application of the refinement.
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Figure 17: Each grid point is surveyed with set of vectors that: a) are blocked by
molecule (black), b) have clear path to box edge (green), or c) are stalled (pink) because
with their finite length they do not reach box edge and thus are considered as having a
clear path. Node 1 is clearly outside the cavity (more clear than blocked paths), node 2 is
clearly inside (more blocked than clear), while node 3 is ambiguous requiring further
examination with shell 2 vectors.
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Figure 18: The fraction of blocked vectors is represented as a contourable scalar quantity
that most impacts the definition of “cavityness” at the mouth.
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Figure 19: Tendrils, very narrow channels and other vague regions are tested with
neighbor count that requires each node to have a minimum number of neighbors defined
to be inside the cavity. The nodes indicated in yellow are subject to this filter, which may
be applied recursively. Not shown: each closed solid contour must have a minimum
volume or it will be deleted.
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4.3.2 Overview of Protein Structure Studies
We carried out a systematic investigation of VICE on a diverse set of proteins to locate
and investigate the indentations, cavities, pockets, grooves, channels and surface regions
on these proteins. The dataset consisted of examples of proteins from the literature
having binding pockets of diverse shapes and sizes. All protein structure coordinates,
retrieved from the RCSB (www.rcsb.org) 162, were prepared as described in the Methods
section. Our test set included: 16 cases where the binding pocket is a well-defined, wellenclosed, deeply buried pocket; 9 cases where the cavity or groove is on the protein’s
surface; 10 cases where the cavity is created by a protein–protein interface (more
challenging since protein–protein dimers do not often show deep well-defined cavities
that are putative binding sites for small molecules); 10 cases of cavities at DNA- or
RNA-protein interfaces; 5 cases of protein structure pairs with very flexible binding
pockets due to movements of flexible loops resulting in both open and closed cavities; 5
cases of proteins with channels or tunnels, i.e., ion channels, porins, and ligand gated
channels; and lastly, 4 cases of proteins with multiple and/or allosteric sites including
some with adjacent auxillary sub-pocket sites that may have additional biochemical roles.

A variety of metrics can be obtained or calculated for protein cavities. Of the most
potential interest is the cavity volume that can be reported in terms of both its ligandoccupied and unoccupied fractions. Figure 20 illustrates how these metrics are calculated
through manipulation of integer grid maps.

We have also derived an automated

algorithmic method (Figure 21) to estimate the cavity cross-sectional entrance areas.
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Figure 20. Cavity Volume Metrics. The volume of the cavity (VC) is indicated by
yellow shading, the volume of the ligand (VL) is indicated by vertical green bars, the
volume of the ligand occupying the cavity (VO) is the intersection of VC and VL, i.e.,
yellow shading + green bars. The unoccupied cavity volume is VC – VO, and the volume
of the ligand outside the cavity is VL – VO.
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Figure 21: Cavity Entrance Calculation. The cavity entrance is calculated from the
derivative of the map illustrated in Figure 18. Vectors are projected from each grid node
toward the center-of-gravity of the cavity (dashed lines); the path (as in Figure 16) is
determined and the absolute value of the difference between the starting grid point and
the first node on that path is calculated as the derivative. Paths completely inside or
outside will have close to zero slope (white), paths clearly crossing from outside to inside
will have slope values close to one (dark red), while the ambiguous cavity mouth grid
points will have intermediate slope values.
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These volume and area metrics for the 64 biomacromolecules, some with multiple
pockets or symmetry-related sites, in this study are set out from Table 4 to 10. Lastly,
identification of protein residues and/or atoms lining the cavity may also be useful
information for drug design and/or site-directed mutagenesis studies. These data are
indicated below for a few cases, but are readily available from the analysis module in the
algorithm. In the following paragraphs we focus on several examples, and present,
somewhat qualitatively, the level of success the VICE algorithm has obtained in
describing these cavities for a broad range of variations in the architecture of binding
pocket viz. deeply buried binding pockets, cavities at protein-protein dimer, and with
DNA/RNA interface. The method is able to detect cavities, shallow grooves, cleft and
channels within a protein. The program also addresses the problem of defining the limits
of a cavity, especially its boundary with free space, i.e., at the entrance (vide infra).
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4.3.3 Well-enclosed Cavities/Deeply Buried Pockets
In the initial examples, we characterized deeply buried binding pockets that are, in other
terms, well-enclosed cavities. These cases also may be thought of as essentially closed
continuous volumes in the interior of protein molecules. While these binding pockets,
which might bind small molecules, are sometimes not obvious from initial inspection,
most available cavity detection software can effectively detect them. Although there may
be a number of these voids inside a protein, it has been observed that the active site is
usually the largest cavity in a protein

168,173

because a large pocket provides increased

surface area and hence increased opportunity for small molecule binding. Thus, one of
the problems faced by these algorithms is identifying the primary binding pocket amongst
(often) numerous small clefts and voids. In addition, the boundary of the active site is
often not well demarcated and numerous snake-like tendrils can project from the binding
envelope. An important success factor of a cavity detection algorithm is in presenting a
single, clean well-bounded cavity.

Prostaglandin H2 synthase (PDB 1eqg) is an example of this class of cavity. A detailed
structural analysis of NSAID binding with prostaglandin H2 synthase is discussed by
Selinsky et al.

194

. Figure 22 illustrates this protein and its detected cavity. The inset at

the upper left shows the relatively small opening (calculated as 22 Å2 by our algorithm)
while the inset at the lower left extracts the cavity, ligand and surrounding residues
(Pro86, Ile89, His90, Leu93, Met113, Val116, Arg120, Phe205, Val344, Ile345, Tyr348,
Val349, Leu352, Ser353, Tyr355, Leu357, Leu359, Phe381, Leu384, Tyr385, Trp387,
His513, Phe518, Glu520, Met522, Ile523, Glu524, Gly526, Ala527, Ser530,
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Figure 22. Well-enclosed Cavity: Prostaglandin H2 synthase. Prostaglandin H2
synthase (1eqg) examined with the VICE algorithm and displayed with MOLCAD and
Sybyl. a) The protein Connolly surface is displayed with opaque rendering. The small
opening to the cavity is indicated by the red arrow; b) the ligand, ibuprofen rendered in
CPK (space-filled), and the residues lining the cavity are shown. The yellow translucent
surface illustrates the extents of the cavity. The protein is rendered with a translucent
Connolly surface; c) shown as in b) but displaying the entire protein.
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Leu531 and Leu 534). The cavity volume is estimated at 814 Å3 of which only 214 Å3
are occupied by ligand. We have not included any volume contribution from water in
calculated volume estimates as the number of water molecules detected by x-ray
crystallography varies greatly with crystallographic resolution 195.

Similarly, the anti-malarial compound fosmidomycin binds to IspC (PDB 1onp)

196

and

the detected cavity is well-defined (Figure 23), surrounded by residues Ser151, Glu152,
Gly185, Ser186, Gly187, Gly188, Trp212, Ser213, Ile218, Ser222, Asn227, Lys228,
Glu231, Ser254, Met276 and a Mn ion. Here, the binding site is deeply buried with a
volume of 342 Å3, while the volume of fosmidomycin is 136 Å3 of which 127 Å3
occupies the active site. Most cavities in this class have opening surface areas that are
about 10% or less of the total cavity surface area and have occupancy factors of around
35-50% (See Table 4).
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Figure 23. Well-enclosed Cavity: IspC. IspC (1onp) examined with the VICE
algorithm and displayed with MOLCAD and Sybyl. a) The protein Connolly surface is
displayed with opaque rendering. The relatively small opening to the cavity can be seen;
b) the ligand, the anti-malarial compound fosmidomycin rendered in CPK, and the
residues lining the cavity are shown. The yellow translucent surface illustrates the extents
of the cavity. The protein is rendered with a translucent Connolly surface and the spacefilling magenta sphere is the manganese ion; c) shown as in b) but displaying the entire
protein.
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Table 4: Protein cavity data for deeply buried pockets

4.3.4 Groove/Cleft on the Surface of a Protein
The more shallow cavities and surface grooves are also potential sites for binding of
drugs, ligands, proteins and other biomacromolecules.

Identification and size

characterization of surface pockets and occluded cavities are often the initial steps in
protein structure-based drug design. The most important of these binding pockets are
generally found to be particularly large and deep clefts. While internal cavities are fairly
easy to define as they generally correspond to well-enclosed regions completely bounded
by surrounding atoms, in many cases interactions between protein and small molecule
tend to involve what can appear to be a nearly planar surface on the surface of the
protein. However, on the nano-scale protein surfaces are irregular with many clefts and
grooves of varying shapes and sizes, and it is often difficult to define the boundaries of
these shallow pockets. In particular the “open” boundary at the mouth is ambiguously
defined even in the best of circumstances with this class of protein cavity. Our algorithm,
as described in Figure 15-21, defines this boundary in terms of a user-adjustable
parameter that represents the ratio of vectors finding the cavity wall over all vectors for
each grid point. For this work we used the default value of 0.5 for this parameter. Most
shallow cavities can be characterized one key metric: they generally have opening crosssectional areas (Table 5 ) of about 30% of the total cavity surface area.

114

115

Table 5: Protein cavity data for cavity from surface depression

One example of a shallow cavity on the surface of protein is illustrated with cytokine
interleukin-2 (1m48)
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in Figure 24. Here, the binding site is mapped to a shallow

groove on the surface of protein. This particular protein is a symmetric homodimer so
that there are two essentially identical binding sites. Cytokine interleukin-2 has been
implicated as one of the principal mediators in proliferation and differentiation of
activated cells in an immune response. It attaches through its surface to the trimeric IL2R receptor, thereby triggering an immune response. Although the binding pocket is
actually present as a surface cleft divided by a ridge, the cavity detection algorithm was
able to capture both sides of the pocket. Interestingly, while a large portion of the ligand
hangs out of the pocket, the two terminal ends are buried within the pocket.
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Figure 24. Shallow Cavity on Protein Surface: Cytokine interleukin-2. The cytokine
interleukin-2 dimer (1m48) has one essentially identical shallow cavity binding site on
each of the two chains. a) The inhibitor Ro26-4550 is bound in the cavity of chain A: the
cavity extents are displayed as the orange contour volume. Both ends are well-bound but
much of the middle of the ligand is external to the cavity; b) both sites are displayed in
this view of the entire protein.
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In another example, as illustrated in Figure 25, a cavity was identified on the surface of
the BCL-XL protein (1bxl, 2yxj) 198,199, a pro-survival protein whose function is regulated
by the binding of anti- or pro-apoptotic factors. Several anti-apoptotic proteins can bind
to the BH3 domain of BCL-XL in tumor cells where it is overexpressed.

These

interactions increase the survival rate of the cancer cell and may contribute to drug
resistance. In contrast, pro-apoptotic proteins such as BAK can induce apoptosis by their
binding to the BH3 domain; thus, the BH3 domain on BCL-XL could be exploited as an
attractive drug target in cancer chemotherapy.

The BH3 domain has a largely

hydrophobic surface with an estimated volume of 1300 Å3. The lower left inset of Figure
25 shows BAK bound to the BH3 domain of BCL-XL (1bxl). The associated cavity is
indicated in yellow. However, a smaller sub-pocket (indicated in orange) can also be
identified on the BH3 domain that binds small molecule modulators such as ABT-737
(2xyj) as shown in the upper right inset of Figure 25. The overlap of these two sites is
shown in the central portion of Figure 25, and suggests that the bound ABT-737 ligand
would block the binding of BAK.

Exploitation of such cavities and sub-pockets at the interface between proteins could have
important implications in drug discovery as more is learned about the role of proteinprotein interactions in biological processes.
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Figure 25. Shallow Cavity on Protein Surface: BCL-XL. Two structures of the BCLXL protein with BAK protein and inhibitor ABT-737 bound within its binding cavity. a)
BCL-XL protein (1bxl) with sixteen residue BAK protein (red capped stick
representation) bound within the surface cavity (yellow translucent envelope); b) BCLXL protein (2yxj) with ABT-737 inhibitor (blue capped sticks) bound in a relatively
smaller sub-pocket (orange translucent surface); c) overlap superposition of 1bxl and
2yxj structures showing the correspondence of the two pockets. Cavity extents illustrated
with yellow and orange translucent envelopes.
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4.3.5 Cavity Formed at a Protein-Protein Interface
Next, we consider examples of cavities at protein–protein interfaces. These interactions
have an important role in many biological processes and cavities at the interface of
protein-protein dimers offer particularly attractive, but as yet largely unrealized,
opportunities for therapeutic intervention. However, uncertainties owing to the structural
changes due to domain movement upon binding and the often insufficient knowledge of
well-defined binding pockets, coupled with the irregular shape and size of typical
protein–protein interfaces, have made it difficult to design inhibitory ligands that can
modulate protein-protein interactions. Although a large surface area is usually buried on
each side of the actual interface, there is often only a relatively small cavity or groove
where a small molecule can fit and thus inhibit the protein-protein interaction. Our cavity
detection algorithm is able to identify and delineate these binding sub-pockets on large
interfaces as described in the section above. Detailed information related to volume,
surface area and chain, residues that line the pocket is also illustrated (see Table 6).
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Table 6: Protein cavity data for cavity formed at protein-protein interface

However, in some cases, cavities at protein-protein interfaces can be observed, either at
the joint between two subunits of the same protein or for a protein-protein complex. In
one example, for αβ-tubulin (1z2b) (Figure 26) 200, our cavity detection algorithm defined
the binding envelope at the wide interface between protein-protein units. Tubulin is the
basic building block of microtubules, critical for mitosis and cell division, and an
important target for anti-cancer drugs.

Tubulin exists as a heterodimer and joins end-to-end to form a protofilament with
alternating α and β subunits. The staggered assembly of 13 protofilaments forms hollow,
cylindrical microtubule filaments. Three distinct binding sites have been identified on
tubulin heterodimers for the taxol, colchicinoids and vinca classes of drugs. Although
Taxol binds wholly on the β subunit, the colchicine binding site lies at the intradimeric
interface of α and β subunits of tubulin and the vinblastine binding site is located at the
interdimeric interface of αβ-subunits. The colchicine and vinblastine binding sites have
been difficult to map as these binding pockets are poorly demarcated between the subunit
interfaces and the crystallographic resolution is rather poor at 3.58 Å. However, our
algorithm was able to clearly identify and delineate binding envelopes at these subunit
interfaces: the colchicine binding site (Figure 26, left inset) has a volume of 842 Å3 with
an opening directly at the α-β interface with a estimated opening area of 28 Å2; and the
vinblastine site cavity has an estimated volume of 1457 Å3 and an opening of 381 Å2.
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Figure 26. Cavity at Protein-Protein Interface. a) The tubulin protein (1z2b) with
colchicine and vinblastine binding sites at interfaces between the α and β subunits. The
tubulin polymer is rendered in ribbon and tube with the α subunits shown in red and β
subunits shown in blue; b) inset shows the colchicine binding pocket (yellow contour) at
the intra-dimeric interface of the αβ-subunit; c) inset shows the vinblastine binding site
(orange contour) at the inter-dimeric interface between αβ-subunits.
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4.3.6 Cavity Formed at a Protein-Polynucleotide Interface
Protein-DNA/RNA interactions primarily are related to regulation of gene expression and
are thus associated with important functions. Cavities or pockets formed by proteins at
protein-nucleic acid interfaces are designed to mediate interactions and allow sequencespecific recognition of a gene. Each nucleic acid binding motif on a protein consists of a
specific binding pocket that recognizes and stabilizes the DNA/RNA. To bind in this
fashion a protein must make contact with the nucleic acid in such a way that the
nucleotide sequence can be recognized. Ligands that can interfere with this recognition,
either by occupying the putative nucleic acid binding site and blocking DNA/RNA
binding, or by exploiting cavities formed in the protein-polynucleotide complex, may be
therapeutically significant. As an example of the latter strategy, Figure 27 shows binding
pockets detected on the 30S ribosomal subunit (1fjg)

201

. Three well-defined major

cavities are detected indicating the binding sites for the antibiotics spectinomycin,
paromomycin and streptomycin. The binding pocket for spectinomycin, which inhibits
elongation factor G catalyzed translocation of the peptidyl-tRNA from the A-site to the
P-site, has a volume of 633 Å3 with spectinomycin completely enclosed within the cavity.
The majority of interactions are with RNA bases C1063, G1064, C1066, G1068, C1069,
A1191, C1192, G1193, U1194, G1386, G1387, with protein residues Ala121 & Gly 122
lining the cavity envelope. Paromomycin, an aminogycoside, binds in the major groove
at the decoding center on H44 and induces errors in translation by increasing the affinity
and stability of tRNA for the A-site.
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Figure 27. Cavity at Protein/Polynucleotide Interface. a) The 30S ribosomal subunit
(1fjg) is rendered as ribbon and tube, except within 20 Å of binding region where a
MOLCAD surface display is shown to highlight the binding pockets for the antibiotics
spectinomycin, paromomycin and streptomycin; b) the binding site for paromomycin
(orange envelope) and streptomycin (yellow envelope) are illustrated. The antibiotic
drugs are rendered in spacefill; c) the binding pocket for spectinomycin (yellow
envelope) is illustrated.
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The volume of this cavity is 1605 Å3 and it is lined by bases C1404, G1405, U1406,
C1407, A1408, C1409, G1410, G1488, G1489, C1490, G1491, A1492, A1493, G1494,
U1495, C1496, G1497 and protein residue Lys47. Adjacent to this binding pocket is a
third cavity which binds streptomycin, a drug that inhibits protein synthesis by interfering
with the initial selection and proofreading of tRNA. The volume of the predicted binding
pocket is 988 Å3 with numerous nucleotides from 16S RNA and residues from the S12
protein lining the binding envelope. While a limited numbers of base pairs are involved
in recognition and stabilization, designing an inhibitor that binds at an interface must
involve sufficient nucleic acid and protein contact so that the ligand fits snugly.

Detailed analysis of cavities formed at the protein-polynucleotide was carried out and
information retrived is tabulated in table 7.
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Table 7: Protein cavity data for cavity formed at a protein-polynucleotide interface.

4.3.7 Flexible Cavities with Loop or Domain Movements
All proteins have an intrinsic flexibility that is required for a wide range of biochemical
processes in catalysis, regulation, and protein assembly. However, in some cases
experimental evidence has indicated that the shape and size of the ligand binding
envelope may change due to domain movements; e.g., molecular recognition and ligand
binding is induced by large loop movements where flexibility in the protein main chain
influences the ligand binding202. Ligand binding may involve a wide range of structural
changes in the receptor protein, from hinge movement of entire domains to small sidechain rearrangements in the binding pocket residues. Many protein functions in fact
involve conformational transitions that involve opening and closing of relatively rigid
parts of that protein about flexible joints. The analysis of side chain flexibility gives
insight valuable for improving docking algorithms and for ligand design when domain
movement and/or loop flexibility opens and closes the binding pocket. Instead of welldefined binding pockets, most proteins that have ‘induced’ domain movement lack deep
clefts or clearly shaped binding pockets. Thus, this is an interesting case study for cavity
detection – where the change in the size and shape of binding pocket due to domain
movement is calculated by comparison between pairs of holo and apo proteins (See Table
8).
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Table 8: Protein cavity data for cavites with loop or domain movements.

Figure 28 shows the example of citrate synthase, 5cts 203 and 5csc 204, which are the apo
(unliganded) and holo (ligand-bound) forms with cavity volumes of 439 Å3 and 967 Å3,
respectively. The bound ligand, oxaloacetate, which has a volume of 704 Å3, appears to
induce this large domain movement in the enzyme and causes binding pocket residues to
undergo side-chain conformational changes as well as changes in overall shape.

Residues His238, Asn242, Leu273, His274, Val314, Val315, Gly317, Tyr318, Gly319,
His320, Ala321, Arg329, Gln364, Ala367, Ala368, Asn373, Asp375, Phe397 surround
the binding pocket in the closed structure, while only residues His238, His274, His320,
Arg329, Asp375, and Phe397 line the unliganded pocket.
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Figure 28. Flexible Cavity with Loop or Domain Movement. The citrate synthase
protein, 5cts (red) and 5csc (blue), the apo (unliganded) and holo (ligand-bound) forms,
respectively, is illustrated. A relatively smaller binding pocket is detected in 5cts (orange
envelope); however, the native ligand oxaloacetate (green capped sticks) induces a
domain movement that significantly alters the shape and size of the binding pocket
(yellow envelope) in 5csc.

131

4.3.8 Multi-Domain Proteins with Channels or Tunnels
Understanding the structure and function of channels and pores within biomolecules is
important, e.g., to a large number of critical disease states and in compensating for drug
resistance due to efflux. Channels and pores and other passages across cell membranes
facilitate the movement of small molecules and ions. These transmembrane proteins,
such as ion channels, transporters and G-protein coupled receptors, are exceptionally
significant drug targets. Apart from this, channels and tunnels also facilitate the access
and exit for substrates/products in some catalytic processes. Channels/pores are often
dynamic in nature and can be relatively flexible in size and shape and access through
them is often regulated by small molecules binding to an active site. Thus, while many of
the available algorithms and associated programs developed to detect and characterize
binding pockets are successful with well-enclosed pockets and surface grooves, for the
most part these procedures fail to detect long, twisted tunnels connecting the interior of a
binding pocket to the exterior environment.

In fact, it is surprisingly difficult

mathematically to differentiate between true channels and tunnels and random voids if
the tunnel has a narrow diameter or constriction point(s).

With the recent availability of crystal structures for large membrane-bound proteins,
detection and mapping of the interior of these channels can give insight into the binding
process for design and development of more selective drugs.

Our cavity detection

algorithm provides sufficient flexibility and interactivity to map binding sites as well as
the channels and tunnels through a protein (See Table 9).
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Table 9: Protein cavity data for proteins with channels or tunnels.

In the example illustrated in Figure 29, the KcsA potassium channel (1j95)

205

, we

applied our cavity detection algorithm to first identify the binding pocket inside the
channel, which is occupied by tetrabutylammonium in this structure. This was easily
detected with the program’s default parameters, e.g., a grid resolution of 1.0 Å. Next, by
decreasing the grid spacing to 0.3 Å, the program successfully identified and delineated a
long, narrow porous channel traversing the entire length of the protein’s transmembrane
axis. It should be noted that this latter calculation was resource intensive due to the very
large number of surveyed grid points, but this level of computation was necessary in
order to adequately sample the protein structure.

The total volume of channel was

calculated to be 1342 Å3 with the binding cavity of 615 Å3, while the
tetrabutylammonium occupies 168 Å3 inside the binding cavity of the channel and is
well-enclosed by hydrophobic residues.
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Figure 29. Channels and Tunnels. a) The KscA K+ ion channel (1j95) plotted with
translucent MOLCAD surface. The binding pocket at the center of the channel is
illustrated with an orange contour map; its tetrabutylammonium inhibitor is rendered in
CPK (space-fill). The channel, traversing the entire length of the protein, is highlighted
with the yellow contour map. Detection of the channel required calculations with a very
large number of grid map points and high resolution. The potassium ions are rendered as
the red spheres; b) expanded view of the inhibitor binding cavity.
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4.3.9 Multiple Cavities and Allosteric Binding Pockets
The detection of auxiliary binding sites is becoming increasingly crucial as many proteins
have more than one biochemical role and are likely to employ separate binding sites in
performing these distinct biochemical tasks.

Allosteric binding pockets may offer

additional recognition sites that modulate the catalytic function of a protein. These
auxiliary binding pockets may be located far away from the catalytic site, as in case of
glycogen phosphorylase, or may overlap with the active site. Traditionally, allosteric
sites were considered to be distal binding sites for molecules that modulate the function
of a protein by a feedback mechanism.

While the mechanisms of allosteric modulation of proteins have been extensively studied,
discovery efforts to efficiently identify and characterize these binding sites continue as
exploiting them may lead to development of entirely new classes of drugs. However, it
can be a non-trivial matter to find and characterize allosteric binding sites when these
sites are present as auxiliary pockets overlapping with the main active site. Figure 30
illustrates an example of an allosteric site on glycogen phosphorylase b (1c50)
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. The

crystal structure shows an allosteric binding site for the co-crystallized molecule
CP320626. Our program identified this binding site with a volume of 431 Å3 close to the
AMP binding site with a volume of 728 Å3. The main PLP catalytic site, with a volume
of 849 Å3, is about 30 Å distant from the allosteric site.

Table 10 shows detailed analysis of other proteins with auxillary and allosteric pockets.
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Figure 30. Auxiliary and allosteric sites. The glycogen phosphorylase b (1c50) with
multiple binding pockets. a) A close-up view of the allosteric/auxiliary site. The AMP
cofactor (red sticks, green cavity contour) and allosteric site (yellow contour) with
inhibitor CP320626 (blue sticks) are in separate subsites of the overall surface groove
(orange contour); b) the main catalytic site (cyan contour) is bound with PLP and is quite
deeply buried in the protein.
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Table 10: Proteincavity data for proteins with multiple cavities and allosteric binding pockets.

4.4 Summary and Outlook
The identification, delineation and visualization of protein active sites is a critical facet
of drug design. These site topographies play crucial roles in molecular recognition.
Proteins may have many pockets and cavities of various sizes, some of which whose
function, e.g., protein-protein interaction, is unknown; it is possible that some may be
usefully exploited with selective molecules that bind and modulate that protein’s
function.

Thus it is important to be able to characterize these binding pockets,

quantitatively and qualitatively. This algorithm and program provides a simple and
interactive tool for locating and delineating all the cavities, pockets, grooves, clefts and
tunnels of a protein whose structure is known. In most cases the default parameters
produce good results very rapidly because the majority of the calculations are performed
with integer arithmetic. Thus, we believe that this tool could be a useful starting point for
virtual screening by automatically identifying potential binding sites in a first pass. Of
course, more reliable and biologically meaningful results will be obtained if the user can
focus on particular regions or features by selecting one or more of the pockets and
investigating them in detail by adjusting a relatively small number of calculational
parameters.

A second major advantage of this program is that it calculates a fairly extensive set of
metrics describing a binding pocket and its occupants. Cavity volumes, cavity surface
areas, and lists of atoms, residues and/or chains lining the binding pocket can be
retrieved. The estimated cross-section surface area of cavity openings is particularly
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interesting as it may suggest methods to describe the maximum size of ligands to enter a
site.

With this rapid and robust cavity algorithm in place, we are exploring virtual screening
and docking algorithms that use property-encoded cavities, e.g., the HINT complement
map, as first stage targets. Such cavity maps would be inherently suited for grid-based
pose generation and scoring.
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CHAPTER 5

Complexity in Modeling and Understanding Protonation States:
Computational Titration of HIV-1 Protease Inhibitor Complexes
5.0 Abstract
The computational titration algorithm based on the “natural” HINT (Hydropathic
INTeractions) force field is described. The HINT software model is an empirical, nonNewtonian force field derived from experimentally measured partition coefficients for
solvent transfer between 1-octanol and water (LogPo/w). The titration algorithm allows the
identification, modeling and optimization of the multiple protonation states of residues
and ligand functional groups at the protein-ligand active site. The importance of taking
into account pH and ionization states of residues, which strongly affect the process of
ligand binding, for correctly predicting the binding free energy is discussed.

The

application of the computational titration protocol to a set of six HIV-1-cyclic inhibitor
complexes is presented and the advance of HINT as a virtual screening tool is outlined.

141

5.1 Introduction
A typical problem in modeling biomolecular systems or molecular recognition systems is
accurately modeling the energetics of binding. Thermodynamic analyses of proteinligand interactions not only give vital insight into the free energy changes of the system,
but also elaborate whether an interaction is enthalpy or entropy driven207-209. Calculation
of binding free energy involves evaluation of both enthalpic and entropic contributions
and forms an integral part of structure-based drug design protocols210,211. To this end,
computer simulations have strived to predict binding free energy and concomitantly
interpret experimental data.

The fundamental idea behind development of robust

computational models was to incorporate as much of the physiochemical parameters
defining protein-ligand interactions as possible212.

These models can contribute

significantly to the understanding of the structural and energetic basis of biomolecular
interactions, with the goal of de novo predicting the binding free energy of protein-ligand
complexes.

Generally, enthalpic contributions are estimated by theoretical methods, knowledgebased potential functions, or parameters derived from experimental data213. The forcefields used for calculations of free energy and intermolecular interactions assume that
steric and electrostatic forces are sufficient to account for the observed biological
interactions213. However, these terms alone are never sufficient for accurate prediction of
biomolecular interactions as they do not always include solvation/desolvation effects.
The entropic contributions to binding are much less well-defined and often poorly
quantitated or even ignored in most cases. Most approaches sum up these interactions
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separately as distinct enthalpic and entropic contributions, whereas, in reality, the ligandprotein recognition is a concerted event and thermodynamic quantities cannot be just
simply added up214. The phenomenon of solvation/desolvation within the protein active
site, resulting in hydrophobic interactions and other phenomena, has been particularly
difficult to model computationally. However, developments in free energy calculation
over the past several years have made significant progress towards this goal215,216.
Among the methods currently available to calculate free energy, those based on complex
and time-consuming molecular dynamics simulations, with explicit consideration of
water molecules, have been shown to correlate fairly well with free energy. Free energy
perturbation (FEP) calculations, based on statistical mechanics, can predict the free
energy of a system by analyzing ensemble averages (calculated by molecular dynamics
(MD) or Monte Carlo (MC) simulations) and treating solvent molecules and ions
explicitly217. Unfortunately, besides being computationally expensive, calculation of free
energy using MD or MC is plagued by errors and problems from a variety of sources218.
Thus, computational time and uncertainty is compounded for complex biomolecular
systems with solvents and counterions218,219.

∆Gbinding values computed via sophisticated simulations often do not correlate well with
experimental binding measurements. This could be due to several reasons. First, it is
becoming common practice in the drug discovery community to use assays generating
IC50s

rather

than

equilibrium

constants,

and

computational

scientists

often

interchangeably use IC50 instead of Ki or Kd to calculate free energies. Furthermore, the
experimental binding data itself present uncertainties, i.e., there are often differences of
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one order of magnitude (corresponding to about 1 kcal mol-1) between inhibition data
collected in different laboratories, and thus they are not always of a quality to enable
accurate quantitative correlations with computational data. On the other hand, structural
data available from x-ray crystallography and NMR has undeniably fostered an
understanding of the biological complexity of molecular recognition. However, often
only partial agreement between experimental and theoretical binding energy data based
on crystal structures has been observed.

It is difficult to correlate solution binding data and crystallographic structural data
because of a number of inherent experimental limitations. Biomolecular interactions are
sensitive to subtle changes in experimental conditions such as pH, buffer, ionic strength,
and temperature under which data are collected220. While the pH used for making the
binding measurements is generally perceived as the pH at which binding takes place, that
pH may not actually be the optimum pH for binding. This discrepancy is magnified
when crystals for x-ray analysis are grown under a still different pH condition. Unless at
very high resolution, an x-ray structure by itself reveals little direct information regarding
the protonation states of the active site residues in a protein. As protein-ligand specificity
and stability are known to be sensitive to structural details, presumably because
protonation states of ionizable residues and the details of the hydrogen-bonding network
are very important for optimum interaction, it is imperative to identify, characterize and
understand the protonation states of residues. Even a change in the ionization state of a
single residue or ligand functional group may have a profound effect on the results for
structure-based energy calculations.

144

In general, molecular association depends on the ionic strength and pH of the solution220.
Protein crystals may contain between 30% and 70% solvent221, which includes the buffer
solution as well. These solvent molecules and ions are distributed among the protein
molecules of the crystal lattice. However, due to their inherent electrostatic properties,
they may distribute themselves in different solvent channels depending on the nature of
the residues lining these solvent pockets. Thus, pH influences ligand binding both
directly, by changing the hydrogen-bonding character of ionizable site residues, and
indirectly, by altering the shape and properties of the site with specifically bound solvent
molecules222,223.

Another significant factor in quantitative estimation of interaction

strength is the microscopic dielectric constant, which is almost never known224. While
many approximations can be made for the dielectric constant of the protein interior225,226,
the most accurate modeling of dielectric effects within proteins requires consideration of
the atomic polarizabilities of the heterogeneous protein and the solvent (both water and
counter ions)227,228.

However, the size of a typical protein-ligand system renders

approaches of this nature very computationally expensive; thus, simplified models that
use macroscopic dielectric models – uniform or distance dependent – are generally
applied229.

In order to accurately predict binding free energies, it is fundamental to take into account
pH, ionization and entropic contributions for virtual screening experiments. However, in
many biomolecular systems the lack of extensive binding and inhibition data as a
function of pH limits the likelihood of good correlation between calculated and measured
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binding data. In this chapter we have examined x-ray structures of HIV-1 protease in
complex with several cyclourea and cyclic sulfamide inhibitor analogs. The binding of
ligands to a biological macromolecule is made even more complicated with the presence
of multiple ionizable groups, and the HIV-1 protease/ligand system has several230.
Existing modeling techniques are insufficient to characterize atomic level details of
binding and do not often consider the multiple protonation states and ensemble of
protonation states that can exist in these systems, many of which are quite similar in
energy. We have applied our computational titration protocol, based on HINT
(Hydropathic INTeraction), to analyze and identify the best protonation models for these
complexes. Our main interest in developing the computational titration algorithm is its
ability to identify and optimize all possible protonation states so that rational models with
atomic details can be constructed and applied to modeling ligand binding energetics.

5.2 Materials and Methods
Optimized molecular models of the HIV-1 protease-ligand complexes in this work were
taken from our previous study on the contribution of water molecules to the energetics of
HIV-1/ligand binding101. In that study, the GRID program was used
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for identifying

and placing water in favorable locations that were unoccupied due to crystallographic
uncertainty. In the cyclic urea complexes, only complex 1AJX had crystallographically
detected waters 313 and 313’, while these waters were not experimentally reported for
complexes 1DMP and 1QBT and were positioned with GRID. However, in case of
cyclic sulfamide complexes, crystallographic water 313 and 313’ were experimentally
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confirmed for the three complexes 1AJV, 1G35 and 1G2K except for water 313’ on
1G2K, where it was positioned using GRID.

The modeling programs Sybyl 7.2 (www.tripos.com)78 suite and HINT 3.11S were used
in this study. In the HINT computational titration protocol, the protein, ligand and water
were partitioned as distinct molecules: only hydrogen atoms deemed “semi-essential”,
i.e., only those attached to polar atoms (N, O, S, P) and those attached to unsaturated
carbons were explicitly considered in the model and assigned HINT constants. The
inferred solvent model, where each residue is partitioned based on its hydrogen count,
was applied. The solvent accessible surface area for the amide nitrogens of the protein
backbone were corrected with the “+20” option. All Asp, Glu and His residues within an
8 Å radius of the ligand and the ionizable functional groups on the ligand (amine,
phosphine, carboxylate groups) were selected for titration. In this study only aspartates
were present at the HIV-1 active site and only one ligand had a titratable amine.

Optimization of each protonation state model focuses on exhaustive optimization of the
R–XHn bond dihedral angles that are exhaustively optimized by forcing rotation through
the entire 360°. This rotation positions the polar hydrogens for optimum hydrogen
bonding and intermolecular HINT energy score. The procedure targets primary amine,
hydroxyl and thiol groups on both protein and ligand. Note that the –OH on protonated
carboxylate groups are also optimized in this way. In His the imidazole ring is flipped to
optimize hydrogen bonding, as are the terminal amides of Asn and Gln. All the possible
models were composed and scored using equation 1. Finally, HINT scores were plotted
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as a function of pH for all the models. Normal and Boltzmann-weighted averages were
then obtained for each protonation level.

5.3 Results and Discussion
5.3.1 The Computational Titration Algorithm
The Computational Titration (CT) algorithm is based on the empirical HINT
(Hydropathic INTeractions) free energy non-covalent forcefield92, and involves modeling
of optimum ionization conditions at the binding site99,192. The Computational Titration
methodology allows exploration of the ionization states of active site residues and ligand
functional groups as a function of protonation. This novel method, implemented in the
HINT software, involves building and scoring of distinct protonation models, i.e., a
defined ionization state for each relevant residue or ligand functional group. First, all the
possible ionization states of residues and ligand functional groups are enumerated with
user choices of residue types192,231,232. The illustration of Figure 31 indicates how this is
accomplished. Each box represents a potential position for a proton. With no added
protons there is only 1 model, but with one added proton there are 14 unique models, and
so on. In the example of Figure 31, one of the ligand’s amines is protonated and one of
the two carboxylate oxygens of Asp125 is protonated. The acidic residues Asp and Glu
are usually subjected to titration; the basic residues Lys and Arg are usually kept in their
protonated states, while His is normally selected for titration. The CT algorithm further
allows selection of Tyr and Cys for titration in cases where exploring the ionization of
these residues is desired.

148

Figure 31. Protonation model. Schematic representation of active site ionizable residues
and ligand functional groups subjected to computational titration; in this case for complex
1DMP. Boxes indicate potential protonation sites, i.e., potential positions for protons.
The sole protonation site on amines is indicated by a solid box, whereas the two potential
protonation sites on aspartates are indicated by dotted boxes. (Protons can be placed on
either carboxylate oxygen, but not both). The illustrated model has two added protons:
one of the two amine groups on the ligand and one of the two carboxylate oxygens on
Asp125 are protonated (“occupied” solid boxes); the other carboxylate oxygen is
unavailable for protonation.
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The analogous functional groups on the ligands, i.e., carboxylic acids, amines, aromatic
alcohols and thiols, are user-selectable for titration. Cofactors or water molecules are
also taken into account. The HINT Titration algorithm identifies and exhaustively
optimizes the water molecules that are in potentially bridging positions, i.e., within a 4Å
radius from both protein and ligand, and thus able to interact with both98. During the
computation, each model corresponding to a particular protonation state is built and then
optimized. Here, all rotatable bonds involving polar hydrogens (R-XHn) – including
those newly created via protonations such as the -OHs of carboxylic acids – at both the
protein active site and on the ligand will be examined and exhaustively optimized192 to
maximize hydrogen bonds formation, i.e., by rotation of these bonds through the entire
360°. In addition, Asn and Gln side chain amides are rotated ± 180° and oriented for
optimal interaction.

Simply, this algorithm creates rotameric models that are

isocrystallographic in that all of the models should fit within the experimental electron
density envelopes and be indistinguishable. Next, the algorithm calculates the HINT
score of each rotameric model and creates a table of HINT score as a function of site
charges. From that a “titration curve” can be calculated. To translate the HINT scores to
free energy, we used the equation102:

ΔG = -0.00195 HTOT – 5.543

(11)

Finally, the statistical thermodynamics Boltzmann energy partition function is applied to
each site charge to calculate population-weighted averages of binding free energy for
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each site charge. The Maxwell–Boltzmann distribution from statistical mechanics forms
the basis of understanding classical molecular phenomena in terms of how energy is
distributed in an average sample of states. Mathematically, the Boltzmann distribution
can be expressed in the form:

f (E) = Ae-E/kT

(12)

It gives the probability of any molecule existing in an energy state E as a function of its
free energy. In our case, it elucidates the possibility of an ionization state existing in a
particular energy state as a function of that state’s free energy. The probability decreases
exponentially as the free energy of the state increases. The Boltzmann average energy
weights the energies of each state by these probabilities and is more representative of the
overall ensemble energy than a normal average.

5.3.2 Ionization State Ensemble of HIV-1 Protease.
HIV-1 protease, which has been widely studied because of its crucial role in propagation
of the AIDS virus, but also as a prototypical target enzyme vital for proteolytic cleavage
of viral proteins, is a homodimeric aspartyl protease with 99 amino acid residues in each
subunit230. The active site of the enzyme is situated at the interface between the two
monomers. A conserved water molecule, water 301, located at the HIV-1 protease
symmetry axis and bridging the two subunits, has been observed in all HIV proteaseligand complexes hydrogen bonded to residues Ile50 and Ile150 and to specific
inhibitors. Two other water molecules, water 313233 and its pseudo-symmetrical 313’,
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are largely conserved and crystallographically detected in several HIV-1 protease-ligand
complexes. Initially, protease inhibitors, mostly linear peptide analogues, were designed
such that they coordinated with water 301, linking them to the amide hydrogens of Ile50
and Ile150 on the flaps of the protease dimer. It was observed from several studies that
this water molecule was crucial for the binding of these inhibitors234. Thus, it was
hypothesized that incorporation of the binding features of this structural water molecule
into an inhibitor would energetically favor the binding interactions, increasing both
binding affinity as well as specificity, since this structural water is unique to the aspartyl
proteases and its substitution would be thermodynamically favorable at least partly due to
increased entropy.

Meticulous design of cyclic ureas as HIV-1 protease inhibitors specifically designed to
displace water 301 was reported by Lam et al. in 1994235. An essential feature of this
class of analogues was the carbonyl oxygen that mimicked the hydrogen bonding features
of the key water molecule. Furthermore, the conversion of the flexible linear peptidic
inhibitors into rigid, cyclic structures with restricted conformations provided additional
favorable entropic benefits. The preferred conformations and stereochemistry of these
inhibitors were confirmed by x-ray crystallography235,236 (see Figure 32). The crystal
structures also revealed the hydrogen bonds between the ligand diol groups and the
carboxylates of the catalytic aspartates (Asp25 and Asp125) that serve to anchor the
scaffold in the active site. However, since protons are normally not detected by x-ray
crystallography, there is experimental uncertainty in the correct assignment of the
protonation state of the catalytic dyad.
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Figure 32 . Cyclic inhibitors of HIV-1 protease.
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Careful analysis of all the possible protonation states can reveal more about the hydrogen
bonding, including the possible existence of alternative networks of hydrogen bonds.
This understanding could lead to the design of better inhibitors with greater binding
affinity.

In the current study we examined six HIV-1 protease-inhibitor complexes (see Figure 32)
representing cyclic urea derivatives, SD146 (pdb code 1QBT237), DMP450 (pdb code
1DMP238) and Aha001 (pdb code 1AJX239), and cyclic sulfamide derivatives, Aha024
(pdb code 1G35240), Aha047 (pdb code 1G2K240) and Aha006 (pdb code 1AJV239). For
the cyclic urea analogs the carbonyl oxygen substitutes the position occupied by the
oxygen of water 301 and thus forms hydrogen bonds with Ile50 and Ile150. For the
sulfamide analogs both oxygens of the sulfamide group are engaged in hydrogen
bonding, with one oxygen hydrogen-bonded to the amide nitrogen of Ile50, and the other
to the amide nitrogen of Ile150. The diols are engaged in hydrogen bond networks with
the catalytic aspartates.

The HIV-1 protease active site presents a number of ionizable residues ideally suited for
the computational titration protocol.

In the six HIV-1-ligand complexes ionizable

residues located within 8 Å of the ligand were chosen for titration. The contributions of
waters 313 and 313’ were also included in the calculations. Note that, in a sense, water,
being both a potential hydrogen bond donor and acceptor, may act as a pH buffer by reorientating after a protonation change on a neighboring functional group. Thus, allowing
it to freely rotate is an important component of the CT algorithm. For all complexes, the
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active site residues Asp25, Asp29, and Asp30 on chain A, and Asp125, Asp129 and
Asp130 on chain B were selected for titration, while only the aminic groups on the 1DMP
ligand were subjected to titration. Thus, complex 1DMP has a total of eight ionizable
functional groups – six on the protein and two on the ligand – yielding 2916 protonation
models for building and scoring.

All the remaining complexes have six ionizable

residues at the protein active site – yielding 729 protonation models.

The results of the titration are shown in Figure 33 for each of the six HIV-1-ligand
complexes investigated, where the HINT scores for each protonation model are plotted as
a function of site charge. The normal (arithmetic) average and the Boltzmann average
(statistically weighted average based on site populations) are calculated for each site
charge and the corresponding “titration curves” are obtained. Details of the CT
calculations, i.e., number of models, normal average and Boltzmann average free
energies, for each site charge are listed in Table 11 and 12. With the exception of
complex 1QBT, the titration curves for all the complexes show a bell-like shape,
particularly evident in complex 1DMP (Figure 33b). The 1QBT titration curve (Figure
33a) has a different trend and while the free energy diminishes with protonation, the
curve does not reach a minimum. The ligands considered in this study have mostly
similar chemical structure and size, but the ligand in 1QBT is bulkier with two
substituted benzoimidazole groups. This complex has the highest experimental binding
free energy, but its calculated energy is underestimated by the HINT scoring function.
This could be due to the structure of the ligand itself: possibly the protonation state of the
benzomidazole groups that are not
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Table 11. Computational Titration results for the HIV-1 protease-cyclic inhibitor
complexes: cyclic urea ligands.

PDB

1QBT

1DMP

1AJX

Cyclic Urea Ligands
Normal
Site
Model
Average a)
Charge
Count
[kcal mol-1]

-6
-5
-4
-3
-2
-1
0
-6
-5
-4
-3
-2
-1
0
1
2
-6
-5
-4
-3
-2
-1
0

1
12
60
160
240
192
64
1
14
85
292
620
832
688
320
64
1
12
60
160
240
192
64

a

Boltzmann
Average a)
[kcal mol-1]

-4.67
-5.02
-5.39
-5.72
-6.01
-6.29
-6.53
-8.28
-8.56
-8.83
-9.05
-9.23
-9.37
-9.49
-9.59
-9.71
-7.40
-7.68
-7.81
-7.93
-7.99
-8.00
-7.95

) HINT scores are converted into free energies using eq. (11).
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-4.67
-5.11
-5.55
-5.95
-6.32
-6.65
-6.91
-8.28
-10.09
-11.50
-11.79
-11.82
-11.61
-11.23
-10.69
-10.02
-7.41
-7.79
-7.98
-8.13
-8.21
-8.22
-8.10

Table 12. Computational Titration results for the HIV-1 protease-cyclic inhibitor
complexes: cyclic sulfamide ligands.

PDB

1G35

1G2K

1AJV

Cyclic Sulfamide Ligands
Normal
Site
Model
Average a)
Charge
Count
[kcal mol-1]

-6
-5
-4
-3
-2
-1
0
-6
-5
-4
-3
-2
-1
0
-6
-5
-4
-3
-2
-1
0

1
12
60
160
240
192
64
1
12
60
160
240
192
64
1
12
60
160
240
192
64

a

Boltzmann
Average a)
[kcal mol-1]

-6.65
-6.69
-6.89
-6.95
-6.98
-6.97
-6.93
-6.36
-6.57
-6.78
-6.92
-7.03
-7.10
-7.11
-6.94
-7.17
-7.32
-7.36
-7.31
-7.17
-6.93

) HINT scores are converted into free energies using eq. (11).
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-6.65
-6.82
-7.04
-7.19
-7.30
-7.34
-7.31
-6.36
-6.71
-7.04
-7.34
-7.59
-7.74
-7.67
-6.94
-7.35
-7.66
-7.89
-8.05
-8.15
-8.11
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Figure 33. Computational titration results for the HIV-1 inhibitor complexes analyzed: a) 1QBT, b) 1DMP, c)
1AJX, d) 1G35, e) 1G2K, f) 1AJV. All HINT scores are plotted as a function of site charge; in addition,
normal averages (open triangles) and Boltzmann averages (closed squares) are depicted.

subjected to titration with our current algorithm. The lowest free energy point determined
by Boltzmann statistics – the minimum of the Boltzmann average titration curve – is what
we define to be the “optimal” calculated free energy of binding representing the most
favorable site charge, and by inference pH, for the specific ligand binding. Figure 34
illustrates the best model for HIV-1 protease in complex with the cyclic urea inhibitor
1DMP, for which the titration curve is shown in Figure 33b. While the “best” model is the
one with the highest HINT score and presumably represents the protonation model
corresponding to the best binding, it must be highlighted that there are many models with
similar energy, and that it is likely that many of them coexist, especially at room
temperature or above where binding assays are performed. For 1DMP the best model
corresponds to a -3 site charge, where the two amine groups on the ligand and only Asp
125 on the protein are protonated. As expected, Asp25 and Asp125 are engaged in a
complex network of hydrogen bonds with the ligand’s diols. The two ammonium groups
on

the

ligand

make

hydrogen

bonds

with

Asp29/Asp30/water313,

and

Asp129/Asp130/water313’, respectively. The deprotonated Asp29 and Asp129 residues
are also involved in hydrogen bonds with waters 313 and 313’, respectively.

Experimental and calculated binding free energies for the examined HIV-1 ligand
complexes are reported in Table 13.

The “optimal” site charges, i.e., the optimal

protonation states that correspond to the optimal binding energies calculated by the
Boltzmann statistical analysis, are also reported. The results are encouraging, giving an
average error of ± 2.5 kcal mol-1 in the prediction of binding energy, excluding the outlier

Figure 34. Complex 1DMP. Best model for HIV-1 protease in complex with a cyclic urea
inhibitor (complex 1DMP). Ligand (ball and stick representation, colored by atom type),
key active site residues (titratable aspartates in stick representation, colored by atom type;
Ile50/150 stick representation, orange) and waters 313/313’ (stick representation, magenta)
are highlighted. Asp125 and the two amine groups on the ligand are protonated in this
model. The network of hydrogen bonds at the active site is illustrated with yellow dashed
lines.

Asp125

Asp25

Asp129

Asp29

Asp130

Asp30

Ile50

Ile150
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Table 13: Experimental and calculated optimal (Boltzmann-weighted average) binding
free energies for HIV-1 ligand complexes.

a

Experimental
∆Gbindinga)
[kcal mol-1]

Optimal Calculated
∆Gbindingb)
[kcal mol-1]

1QBT
1DMP
1AJX
1G35
1G2K
1AJV

-14.44
-12.99
-10.79
-11.06
-10.82
-10.52

-6.91
-11.82
-8.22
-7.34
-7.74
-8.15

Optimal
site
charge

0 c)
-2
-1
-1
-1
-1

) Data from.185

b
c

PDB

) HINT scores are converted into free energies using eq. (11).

) 1QBT has not reached a true titration curve minimum. This is the value at the curve’s lowest

point, thus the “optimal” site charge may be at a more positive value (see Figure 33a).
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complex 1QBT where the calculated energy is underestimated by the computational
titration and which displayed an atypical titration profile (Figure 33a). It is important to
recognize that using an equation correlating HINT scores with binding energies that is
calibrated for the specific analyzed system, instead of a general equation, would likely
improve free energy prediction.

5.4 Summary
The computational protocol described here allows modeling of the multiplicity of
protonation states, an often overlooked aspect of structure that has implications for drug
discovery. This approach allows generating hypotheses on the best model for binding, i.e.,
the model with protonation corresponding to the optimal binding energy. The binding
energy is evaluated with the HINT scoring function, which has previously been shown to
fairly accurately predict binding free energies
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. In considering all the ionizable residues

at the active site and modeling all the possible protonation states of residues and functional
groups at this site, the computational titration algorithm represents fairly realistically the
fluxional behavior of hydrogens in solvated biological systems. Hydrogens, in fact, are not
static elements of a real biomolecular system. However, the computational titration
procedure remains computationally expensive. The number of models increases rapidly as
the number of ionizable residues/functional groups in the binding pocket increases. The
inclusion of water molecules in the calculations makes these procedures even more time
consuming. Nevertheless, we are committed to making this tool available and are currently
developing a web-enabled version that will be publicly accessible.
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CHAPTER 6

Conclusions
Computational tools have been extensively used in drug design and development from
exploration of targets to corroborate experimental data. Computer aided drug design has
been used to design new bioactive compounds with the aim of optimizing the overall
pharmacodynamic and pharmacokinetic profile of a drug candidate and expediting the
process of drug discovery. These techniques have substantially reduced the time and
economic resources needed to discover novel drug candidates. This dissertation discussed
the computational modeling aspects of drug design for anti-cancer agents with a focus on
their interactions with potential targets and an emphasis on explaining and suggesting each
drug candidate’s mechanism of action at the molecular level. Molecular modeling studies
and development of computational tools that aid in drug design were also discussed. A
novel de novo program for cavity detection and its application were described. The
software tool identifies and delineates the active site within the protein. Another
computational tool that allows identification, modeling and optimization of the multiple
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protonation states of residues and ligand functional groups at the protein-ligand active site
was also described and discussed.

The compounds which bind to the colchicine site of tubulin have drawn considerable
attention and studies indicated that these agents may influence microtubule dynamics by
inhibiting polymerization. However, fundamental uncertainties in many aspects of
microtubule biology and insufficient knowledge of the binding site interactions have
undermined the possibility of identifying effective drugs with minimal toxicity.
Nevertheless, the compounds which bind to the colchicine site of tubulin have recently
emerged as attractive targets for cancer therapy. Pyrrole-containing molecules derived
from nature have proven to be particularly useful as lead compounds for drug
development. We designed and developed a series of substituted pyrroles that inhibit
growth and promote death of breast tumor cells at nM and μM concentrations in human
breast tumor cell lines. Subsequent experimental studies demonstrated that the highest
degree of antiproliferative activity was expressed by JG-03-14 (3,5-dibromo-4-(3,4dimethoxyphenyl)-1Hpyrrole-2-carboxylic acid ethyl ester). COMPARE analysis across
the NCI panel of cancer cell lines, along with molecular modeling studies, showed that JG03-14 had a similar mechanism of action to colchicine and combretastatin.

The current work demonstrated that molecular modeling docking calculations along with
HINT interaction analysis were able to complement experimental studies of binding in
many aspects, including accurate representation of the complex structure and the binding
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mode of inhibitors. HINT scoring function was used to investigate the structural aspects of
the interactions. On the basis of calculations, the complexes were ranked according to their
decreasing HINT scores. These results, calculated for 22 pyrrole compounds, provide insights
into the structural requirements for the growth inhibitory activity/cytotoxicity of this class of
agents and offer significant opportunity for structural alterations, which could lead to an
improved drug candidate. Complex with JG-03-14 is the most stable corroborating the

experimental data. These results are important for the understanding the binding process
and valuable in the design of new Pyrrole-based colchicine site inhibitors. Compounds of
this type have potential for further development. Hydropathic interaction analysis has
provided a rationale for selecting the substituent on a parent ligand which will yield more
tightly binding analogues.

Stilbenes are a group of natural compounds with many biological activities. The
mechanism of action of stilbenes is by interfering with microtubule polymerization through
the colchicine-binding site. Two highly potent stilbenes, cis-3,40,5-trimethoxy-30aminostilbene (stilbene 5c) and cis-3,40,5-trimethoxy-30-hydroxystilbene (stilbene 6c)
induce G2/M cell-cycle arrest and leukemic cell death in nanomolar range without
affecting normal bone marrow progenitor cells. Animal studies showed that stilbenes are
well tolerated and suppresses tumor growth in mice. Further experimental results indicated
that stilbene 5c is a microtubule- interfering agent and can be potentially useful in
leukemic therapy. A molecular modeling study was carried out to accurately represent the
complex structure and the binding mode of a new class of stilbene-based tubulin inhibitors
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that bind at the αβ-tubulin colchicine site. Computational docking along with HINT score
analysis fitted these inhibitors into the colchicine site and revealed detailed structureactivity information useful for inhibitor design. Quantitative analysis of the results was in
good agreement with the in vitro antiproliferative activity of these derivatives (ranging
from 3 nM to 100 μM) such that calculated and measured free energies of binding correlate
with an r2 of 0.89 (standard error ± 0.85 kcal mol-1). This correlation suggests that the
activity of unknown compounds may be predicted. The results are important for
understanding the binding process and valuable in the design of new stilbene-based
colchicine site inhibitors.

Apart from the application of computational methodologies, design and development of
new computational tools has also been discussed in the manuscript. The development and
implementation of a novel cavity detection algorithm is also reported and discussed. The
algorithm named VICE (Vectorial Identification of Cavity Extents) utilizes HINT toolkit
functions to identify and delineate binding pocket in a protein. This algorithm, which is
based on geometric criteria applied to simple integer grid maps to delineate binding sites,
is very efficient. The program was applied to a representative set of proteins from different
classes having binding pockets of different shapes and sizes. It was demonstrated that the
application is capable of detecting and delineating indentations, cavities, pockets, voids,
grooves, channels, tunnels, pores and surface regions on protein. The interactive front-end
provides a quick and simple procedure for identifying, displaying and manipulating
cavities in a known protein structure. In addition to computing volumes, our method also
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provides information on atoms, residues and chains which contribute to the cavities. These
observations have been most thoroughly characterized and correlate well with the
experimental data.

The study also implemented the computational titration algorithm to understand the
complexity of ligand binding and protonation state in the active site of HIV-1 protease.
The importance of taking into account pH and ionization states of residues, which strongly
affect the process of ligand binding, for correctly predicting the binding free energy is
discussed. The application of the computational titration protocol to a set of six HIV-1cyclic inhibitor complexes was carried out. The binding energy was evaluated with the
HINT scoring function. The results were encouraging, giving an average error of ± 2.5 kcal
mol-1 in the prediction of binding energy. The titration algorithm allowed the
identification, modeling and optimization of the multiple protonation states of residues and
ligand functional groups at the protein-ligand active site. This approach allows generating
hypotheses on the best model for binding, i.e., the model with protonation corresponding to
the optimal binding energy. In considering all the ionizable residues at the active site and
modeling all the possible protonation states of residues and functional groups at this site,
the computational titration algorithm represents fairly realistically the fluxional behavior of
hydrogens in solvated biological systems.

To conclude, the overall purpose of this multidisciplinary endeavour was to design and
develop novel therapeutics for cancer and understand the molecular mechanism involved
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in drug action using computational tools. A second synergistic goal was to develop new
computational tools that will aid in design bioactive molecules and understanding the
molecular mechanism of protein-ligand binding process. To this end, application of
molecular modeling has facilitated the design and development of the new anti-cancer
compounds and has served to improve the understanding of the underlying mechanisms of
microtubule depolymerizing agents. In its most general terms, the overall design and
refinement of the novel antitumor compounds proposed herein is a fundamental step
towards establishing a knowledge base that will enable the synthesis and testing of
effective chemotherapeutic agents. The HINT force field can provide atomic level details
of interactions and may help in the design of more selective drug molecules. The HINT
program finds extensive application in drug design project and the knowledge acquired
will prove to be productive and of scientific significance. This research will further provide
the scientific community with additional knowledge that will help them in the de novo
identification and characterization of binding site and to understand the relevant molecularlevel interactions.
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